消化器がん免疫療法の現在（いま）

出版社： へるす出版
著者：
発行日： 2023-09-19
分野： 臨床医学：一般  >  癌/腫瘍一般
ISBN： 9784867190760
電子書籍版： 2023-09-19
書籍・雑誌
≪全国送料無料でお届け≫
取寄せ目安：約3営業日

6,050 円(税込)

購入する
電子書籍
章別単位で購入
ブラウザ、アプリ閲覧

6,050 円(税込)

購入する

商品紹介

がん治療に携わるすべての方々へ
手術，放射線療法，化学療法に次ぐ第四の治療として認知されるに至った免疫療法を概説。
がん免疫を十分理解し，より安全に効果的に治療を行うための一冊です。

目次

  • １．がん免疫療法の歴史と発展
    ２．がん患者の全身・がん局所で起きている変化
    ３．免疫抑制のメカニズム
    ４．免疫チェックポイント阻害薬の歴史と現状
    ５．免疫チェックポイント阻害薬の将来
    ６．肺がんから学ぶこと； ガイドラインの変更
    ７．化学療法と免疫療法
    ８．BRM療法とサイトカイン療法
    ９．樹状細胞ワクチンとペプチドワクチン療法
    10．消化器がんに対するがん免疫療法の臨床試験と抑制性免疫の解析
    11．免疫細胞療法
    12．ネオアンチゲンを用いたがん治療
    13．複合免疫療法
    14．免疫抑制細胞をターゲットにしたがん治療
    15．抗がん剤・分子標的薬との複合免疫療法
    16．がん免疫サイクルと免疫編集
    17．遺伝子改変T細胞
    18．がん免疫療法の未来に向けて；Beyond The Guideline

    略語一覧

この書籍の参考文献

参考文献のリンクは、リンク先の都合等により正しく表示されない場合がありますので、あらかじめご了承下さい。

本参考文献は電子書籍掲載内容を元にしております。

[1] がん免疫療法の歴史と発展

P.7 掲載の参考文献
1) van der Bruggen, P., Traversari, C., Chomez, P., Lurquin, C., De Plaen, E., Van den Eynde, B., Knuth, A. and Boon, T.:A gene encoding an antigen recognized by cytolytic T lymphocytes on a human melanoma. Science, 254:1643-1647, 1991.
 
2) Brunet, J. F., Denizot, F., Luciani, M. F., Roux-Dosseto, M., Suzan, M., Mattei, M. G. and Golstein, P.:A new member of the immunoglobulin superfamily-CTLA-4. Nature, 328:267-270, 1987.
PubMed
3) Ishida, Y., Agata, Y., Shibahara, K. and Honjo, T.:Induced expression of PD-1, a novel member of the immunoglobulin gene superfamily, upon programmed cell death. EMBO J., 11:3887-3895, 1992.
PubMed
4) Coley, W. B.:II. Contribution to the knowledge of sarcoma. Ann. Surg., 14:199-220, 1891.
 
5) Sakamoto, J., Teramukai, S., Nakazato, H., Sato, Y., Uchino, J., Taguchi, T., Ryoma, Y. and Ohashi, Y.:Efficacy of adjuvant immunochemotherapy with OK-432 for patients with curatively resected gastric cancer:A meta-analysis of centrally randomized controlled clinical trials. J. Immunother., 25:405-412, 2002.
PubMed
6) Nakazato, H., Koike, A., Saji, S., Ogawa, N. and Sakamoto, J.:Efficacy of immunochemotherapy as adjuvant treatment after curative resection of gastric cancer:Study group of immunochemotherapy with PSK for gastric cancer. Lancet, 343:1122-1126, 1994.
 
7) Ito, K., Nakazato, H., Koike, A., Takagi, H., Saji, S., Baba, S., Mai, M., Sakamoto, J. and Ohashi, Y.;Study Group of Immunochemotherapy with PSK for Colon Cancer:Long-term effect of 5-fluorouracil enhanced by intermittent administration of polysaccharide K after curative resection of colon cancer:A randomized controlled trial for 7-year follow-up. Int. J. Colorectal. Dis., 19:157-164, 2004.
 
8) Ohwada, S., Ikeya, T., Yokomori, T., Kusaba, T., Roppongi, T., Takahashi, T., Nakamura, S., Kakinuma, S., Iwazaki, S., Ishikawa, H., Kawate, S., Nakajima, T. and Morishita, Y.:Adjuvant immunochemotherapy with oral tegafur/uracil plus PSK in patients with stage II or III colorectal cancer:A randomized controlled study. Br. J. Cancer, 90:1003-1010, 2004.
PubMed
9) Oba, K., Kobayashi, M., Matsui, T., Kodera, Y. and Sakamoto, J.:Individual patient based meta-analysis of lentinan for unresectable/recurrent gastric cancer. Anticancer Res., 29:2739-2745, 2009.
PubMed
10) Chen, D. S. and Mellman, I.:Oncology meets immunology:The cancer-immunity cycle. Immunity, 39:1-10, 2013.
PubMed
11) Borcoman, E., Nandikolla, A., Long, G., Goel, S. and Le Tourneau, C.:Patterns of response and progression to immunotherapy. Am. Soc. Clin. Oncol. Educ. Book, 38:169-178, 2018.
PubMed
12) Steinman, R. M.:The dendritic cell system and its role in immunogenicity. Annu. Rev. Immunol., 9:271-296, 1991.
PubMed
13) Matsusaki, K.:A new treatment strategy-novel cell-free and concentrated ascites reinfusion system (KM-CART) for massive malignant ascites. Gan To Kagaku Ryoho, 43:2490-2497, 2016.
PubMed
14) Kantoff, P. W., Higano, C. S., Shore, N. D., Berger, E. R., Small, E. J., Penson, D. F., Redfern, C. H., Ferrari, A. C., Dreicer, R., Sims, R. B., Xu, Y., Frohlich, M. W. and Schellhammer, P. F.;IMPACT Study Investigators:Sipuleucel-T immunotherapy for castration-resistant prostatic cancer. N. Engl. J. Med., 363:411-422, 2010.
 
15) Kohler, G. and Milstein, C.:Continuous cultures of fused cells secreting antibody of predefined specificity. Nature, 256:495-497, 1975.
PubMed
16) 大腸癌研究会編:大腸癌治療ガイドライン(医師用2019年版). 金原出版, 東京, 2019, p. 31.
 
17) Kearney, E. R., Walunas, T. L., Karr, R. W., Morton, P. A., Loh, D. Y., Bluestone, J. A. and Jenkins, M. K.:Antigen-dependent clonal expansion of a trace population of antigen-specific CD4+ T cells in vivo is dependent on CD28 costimulation and inhibited by CTLA-4. J. Immunol., 155:1032-1036, 1995.
PubMed
18) Brahmer, J. R., Drake, C. G., Wollner, I., Powderly, J. D., Picus, J., Sharfman, W. H., Stankevich, E., Pons, A., Salay, T. M., McMiller, T. L., Gilson, M. M., Wang, C., Selby, M., Taube, J. M., Anders, R., Chen, L., Korman, A. J., Pardoll, D. M., Lowy, I. and Topalian, S. L.:Phase I study of single-agent anti-programmed death-1 (MDX-1106) in refractory solid tumors:Safety, clinical activity, pharmacodynamics, and immunologic correlates. J. Clin. Oncol., 28:3167-3175, 2010.
PubMed
19) 医薬品医療機器総合機構(PMDA):最適使用推進ガイドライン(医薬品). https://www.pmda.go.jp/review-services/drugreviews/review-information/p-drugs/0028.html
 
20) Lao, Y., Shen, D., Zhang, W., He, R. and Jiangm, M.:Immune checkpoint inhibitors in cancer therapy:How to overcome drug resistance? Cancers, 14:3575, 2022.
 
21) Dunn, G. P., Bruce, A. T., Ikeda, H., Old, L. J. and Schreiber, R. D.:Cancer immunoediting:From immunosurveillance to tumor escape. Nat. Immunol., 3:991-998, 2002.
PubMed
22) Kochenderfer, J. N., Dudley, M. E., Kassim, S. H., Somerville, R. P., Carpenter, R. O., Stetler-Stevenson, M., Yang, J. C., Phan, G. Q., Hughes, M. S., Sherry, R. M., Raffeld, M., Feldman, S., Lu, L., Li, Y. F., Ngo, L. T., Goy, A., Feldman, T., Spaner, D. E., Wang, M. L., Chen, C. C., Kranick, S. M., Nath, A., Nathan, D. A., Morton, K. E., Toomey, M. A. and Rosenberg, S. A.:Chemotherapy-refractory diffuse large B-cell lymphoma and indolent B-cell malignancies can be effectively treated with autologous T cells expressing an anti-CD19 chimeric antigen receptor. J. Clin. Oncol., 33:540-549, 2015.
 
23) Adachi, K., Kano, Y., Nagai, T., Okuyama, N., Sakoda, Y. and Tamada, K.:IL-7 and CCL19 expression in CAR-T cells improves immune cell infiltration and CAR-T cell survival in the tumor. Nat. Biotechnol., 36:346-351, 2018.
 
24) Ando, M., Kondo, T., Tomisato, W., Ito, M., Shichino, S., Srirat, T., Omata, S. M., Nakagawara, K. and Yoshimura, A.:Rejuvenating effector/exhausted CAR-T cells to stem cell memory-like CAR-T cells by resting them in the presence of CXCL12 and the NOTCH ligand. Cancer Res. Commun., 1:41-55, 2021.
 
25) Yoshikawa, T., Wu, Z., Inoue, S., Kasuya, H., Matsushita, H., Takahashi, Y., Kuroda, H., Hosoda, W., Suzuki, S. and Kagoya, Y.:Genetic ablation of PRDM1 in antitumor T cells enhances therapeutic efficacy of adoptive immunotherapy. Blood, 139:2156-2172, 2022.
PubMed
26) Kroemer, G., Galluzzi, L., Kepp, O. and Zitvogel, L.:Immunogenic cell death in cancer therapy. Annu. Rev. Immunol., 31:51-72, 2013.
PubMed
27) Beneteau, M., Zunino, B., Jacquin, M. A., Meynet, O., Chiche, J., Pradelli, L. A., Marchetti, S., Cornille, A., Carles, M. and Ricci, J. E.:Combination of glycolysis inhibition with chemotherapy results in an antitumor immune response. Proc. Natl. Acad. Sci. U. S. A., 109:20071-20076, 2012.
 
28) Hangai, S., Kawamura, T., Kimura, Y., Chang, C. Y., Hibino, S., Yamamoto, D., Nakai, Y., Tateishi, R., Oshima, M., Oshima, H., Kodama, T., Moriya, K., Koike, K., Yanai, H. and Taniguchi, T.:Orchestration of myeloid-derived suppressor cells in the tumor microenvironment by ubiquitous cellular protein TCTP released by tumor cells. Nat. Immunol., 22:947-957, 2021.
PubMed

[2] がん患者の全身・がん局所で起きている変化

P.15 掲載の参考文献
1) Bone, R. C.:Sir Isaac Newton, sepsis, SIRS, and CARS. Crit. Care Med., 24:1125-1128, 1996.
 
2) Bone, R. C.:Toward a theory regarding the pathogenesis of the systemic inflammatory response syndrome:What we do and do not know about cytokine regulation. Crit. Care Med., 24:163-172, 1996.
 
3) Shibata, M., Abe, H., Nezu, T., Kanou, H., Ohara, M., Takekawa, H. and Fukuzawa, M.:Compensatory anti-inflammatory response syndrome (CARS) exists in cancer patients with cachexia. 37th annual meeting of American Society of Clinical Oncology, San Francisco, 2001.
 
4) Shibata, M., Gonda, K. and Takenoshita, S.:Systemic inflammation causing multiple clinical symptoms in gastrointestinal cancer. In Gastrointestinal Cancers:Prevention, Detection and Treatment. Volume 2, ed. by Tyagi, A. K. and Prasad, S., Nova Science publishers, 2016, p. 311-323.
 
5) Oliff, A., Defeo-Jones, D., Boyer, M., Martinez, D., Kiefer, D., Vuocolo, G., Wolfe, A. and Socher, S. H.:Tumors secreting human TNF/cachectin induce cachexia in mice. Cell, 50:555-563, 1987.
PubMed
6) Tracey, K. J., Wei, H., Manogue, K. R., Fong, Y., Hesse, D. G., Nguyen, H. T., Kuo, G. C., Beutler, B., Cotran, R. S., Cerami, A. and Lowry, S. F.:Cachectin/tumor necrosis factor induces cachexia, anemia, and inflammation. J. Exp. Med., 167:1211-1227, 1988.
 
7) Brenner, D. A., Buck, M., Feitelberg, S. P. and Chojkier, M.:Tumor necrosis factor-alpha inhibits albumin gene expression in a murine model of cachexia. J. Clin. Invest., 85:248-255, 1990.
 
8) Fearon, K. C., Barber, M. D., Moses, A. G., Ahmedzai, S. H., Taylor, G. S., Tisdale, M. J. and Murray, G. D.:Double-blind, placebo-controlled, randomized study of eicosapentaenoic acid diester in patients with cancer cachexia. J. Clin. Oncol., 24:3401-3407, 2006.
PubMed
9) Muscaritoli, M., Anker, S. D., Argiles, J., Aversa, Z., Bauer, J. M., Biolo, G., Boirie, Y., Bosaeus, I., Cederholm, T., Costelli, P., Fearon, K. C., Laviano, A., Maggio, M., Rossi Fanelli, F., Schneider, S. M., Schols, A. and Sieber, C. C.:Consensus definition of sarcopenia, cachexia and pre-cachexia:Joint document elaborated by Special Interest Group (SIG) "cachexia-anorexia in chronic wasting diseases" and "nutrition in geriatrics". Clin. Nutr., 29:154-159, 2010.
PubMed
10) Pareira, M. D., Conrad, E. J., Hicks, W. and Elman, R.:Clinical response and changes in nitrogen balance, body weight, plasma proteins, and hemoglobin following tube feeding in cancer cachexia. Cancer, 8:803-808, 1955.
PubMed
11) Peden, J. C. Jr., Bond, L. F. and Maxwell, M.:Comparative protein repletion in cancer and non-cancer cachexia with special reference to changes in blood volume and total circulating plasma protein and hemoglobin. Am. J. Clin. Nutr., 5:305-315, 1957.
PubMed
12) Morrison, D. S.:Origins of nutritional imbalance in cancer. Cancer Res., 35:3339-3342, 1975.
 
13) Nixon, D. W.:The value of parenteral nutrition support:Chemotherapy and radiation treatment. Cancer, 58:1902-1903, 1986.
PubMed
14) Mantovani, G., Maccio, A., Madeddu, C., Serpe, R., Antoni, G., Massa, E., Dessi, M. and Panzone, F.:Phase II nonrandomized study of the efficacy and safety of COX-2 inhibitor celecoxib on patients with cancer cachexia. J. Mol. Med., 88:85-92, 2010.
PubMed
15) Wiedenmann, B., Malfeltheiner, P., Friess, H., Ritch, P., Arseneau, J., Mantovani, G., Caprioni, F., Van Cutsem, E., Richel, D., DeWitte, M., Qi, M., Robinson, D. Jr., Zhong, B., De Boer, C., Lu, J. D., Prabhakar, U., Corringham, R. and Von Hoff, D.:A multicenter, phase II study of infliximab plus gemcitabine in pancreatic cancer cachexia. J. Support. Oncol., 6:18-25, 2008.
 
16) Ando, K., Takahashi, F., Motojima, S., Nakashima, K., Kaneko, N., Hoshi, K. and Takahashi, K.:Possible role for tocilizumab, an anti-interleukin-6 receptor antibody, in treating cancer cachexia. J. Clin. Oncol., 31:e69-e72, 2013.
PubMed
17) Kojima, M., Hosoda, H., Date, Y., Nakazato, M., Matsuo, H. and Kangawa, K.:Ghrelin is a growthhormone-releasing acylated peptide from stomach. Nature, 402:656-660, 1999.
PubMed
18) Nakazato, M., Murakami, N., Date, Y., Kojima, M., Matsuo, H., Kangawa, K. and Matsukura, S.:A role for ghrelin in the central regulation of feeding. Nature, 409:194-198, 2001.
PubMed
19) Hamauchi, S., Furuse, J., Takano, T., Munemoto, Y., Furuya, K., Baba, H., Takeuchi, M., Choda, Y., Higashiguchi, T., Naito, T., Muro, K., Takayama, K., Oyama, S., Takiguchi, T., Komura, N. and Tamura, K.:A multicenter open-label, single-arm study of anamorelin (ONO-7643) in advanced gastrointestinal cancer patients with cancer cachexia. Cancer, 125:4294-4302, 2019.
PubMed
20) Seruga, B., Zhang, H., Bernstein, L. J. and Tannock, I. F.:Cytokines and their relationship to the symptoms and outcome of cancer. Nat. Rev. Cancer, 8:887-899, 2008.
 
21) Shibata, M., Kono, K. and Takenoshita, S.:Inhibiting VEGF in cancer immunotherapy. Clin. Immunol. Comm., 2:12-16, 2022.
 
22) Shibata, M., Inukai, A., Yoshimori, D., Ashizawa, M., Nakajima, T., Takada, M., Yazawa, T., Mimura, K., Inoue, N., Watanabe, T., Tachibana, K., Muto, S., Kono, K., Endo, S. and Takenoshita, S.:Metabolic impact of immune-suppressor cells in cancer patients. J. Surg. Res., 5:134-144, 2022.
 
23) Meyer, C., Cagnon, L., Costa-Nunes, C. M., Baumgaertner, P., Montandon, N., Leyvraz, L., Michielin, O., Romano, E. and Speiser, D. E.:Frequencies of circulating MDSC correlate with clinical outcome of melanoma patients treated with ipilimumab. Cancer Immunol. Immunother., 63:247-257, 2014.
PubMed
24) Berquin, I. M., Edwards, I. J., Kridel, S. J. and Chen, Y. Q.:Polyunsaturated fatty acid metabolism in prostate cancer. Cancer Metastasis Rev., 30:295-309, 2011.
 

[3] 免疫抑制のメカニズム

P.22 掲載の参考文献
1) Schreiber, R. D., Old, L. J. and Smyth, M. J.:Cancer immunoediting:Integrating immunity's roles in cancer suppression and promotion. Science, 331:1565-1570, 2011.
PubMed
2) Chen, D. S. and Mellman, I.:Elements of cancer immunity and the cancer-immune set point. Nature, 541:321-330, 2017.
PubMed
3) Spranger, S., Bao, R. and Gajewski, T. F.:Melanoma-intrinsic β-catenin signalling prevents anti-tumour immunity. Nature, 523:231-235, 2015.
 
4) Wei, S. C., Duffy, C. R. and Allison, J. P.:Fundamental mechanisms of immune checkpoint blockade therapy. Cancer Discov., 8:1069-1086, 2018.
PubMed
5) Huinen, Z. R., Huijbers, E. J. M., van Beijnum, J. R., Nowak-Sliwinska, P. and Griffioen, A. W.:Anti-angiogenic agents-overcoming tumour endothelial cell anergy and improving immunotherapy outcomes. Nat. Rev. Clin. Oncol., 18:527-540, 2021.
PubMed
6) Gabrilovich, D. I., Ostrand-Rosenberg, S. and Bronte, V.:Coordinated regulation of myeloid cells by tumours. Nat. Rev. Immunol., 12:253-268, 2012.
PubMed
7) Murray, P. J., Allen, J. E., Biswas, S. K., Fisher, E. A., Gilroy, D. W., Goerdt, S., Gordon, S., Hamilton, J. A., Ivashkiv, L. B., Lawrence, T., Locati, M., Mantovani, A., Martinez, F. O., Mege, J. L., Mosser, D. M., Natoli, G., Saeij, J. P., Schultze, J. L., Shirey, K. A., Sica, A., Suttles, J., Udalova, I., van Ginderachter, J. A., Vogel, S. N. and Wynn, T. A.:Macrophage activation and polarization:Nomenclature and experimental guidelines. Immunity, 41:14-20, 2014.
 
8) Tcyganov, E., Mastio, J., Chen, E. and Gabrilovich, D. I.:Plasticity of myeloid-derived suppressor cells in cancer. Curr. Opin. Immunol., 51:76-82, 2018.
PubMed
9) Law, A. M. K., Valdes-Mora, F. and Gallego-Ortega, D.:Myeloid-derived suppressor cells as a therapeutic target for cancer. Cells, 9:561, 2020.
PubMed
10) Otsubo, D., Yamashita, K., Fujita, M., Nishi, M., Kimura, Y., Hasegawa, H., Suzuki, S. and Kakeji, Y.:Early-phase treatment by low-dose 5-fluorouracil or primary tumor resection inhibits MDSC-mediated lung metastasis formation. Anticancer Res., 35:4425-4431, 2015.
PubMed
11) Tanaka, T., Fujita, M., Hasegawa, H., Arimoto, A., Nishi, M., Fukuoka, E., Sugita, Y., Matsuda, T., Sumi, Y., Suzuki, S., Kakeji, Y. and Yamashita, K.:Frequency of myeloid-derived suppressor cells in the peripheral blood reflects the status of tumor recurrence. Anticancer Res., 37:3863-3869, 2017.
PubMed
12) Sugita, Y., Yamashita, K., Fujita, M., Saito, M., Yamada, K., Agawa, K., Watanabe, A., Fukuoka, E., Hasegawa, H., Kanaji, S., Oshikiri, T., Matsuda, T., Nakamura, T., Suzuki, S. and Kakeji, Y.:CD244+ polymorphonuclear myeloid-derived suppressor cells reflect the status of peritoneal dissemination in a colon cancer mouse model. Oncol. Rep., 45:106, 2021.
 
13) Wang, P. F., Song, S. Y., Wang, T. J., Ji, W. J., Li, S. W., Liu, N. and Yan, C. X.:Prognostic role of pretreatment circulating MDSCs in patients with solid malignancies:A meta-analysis of 40 studies. Oncoimmunology, 7:e1494113, 2018.
PubMed
14) Hegde, S., Leader, A. M. and Merad, M.:MDSC:Markers, development, states, and unaddressed complexity. Immunity, 54:875-884, 2021.
PubMed
15) Sakaguchi, S., Sakaguchi, N., Asano, M., Itoh, M. and Toda, M.:Immunologic self-tolerance maintained by activated T cells expressing IL-2 receptor alpha-chains (CD25):Breakdown of a single mechanism of self-tolerance causes various autoimmune diseases. J. Immunol., 155:1151-1164, 1995.
PubMed
16) Hori, S., Nomura, T. and Sakaguchi, S.:Control of regulatory T cell development by the transcription factor Foxp3. Science, 299:1057-1061, 2003.
 
17) Bennett, C. L., Christie, J., Ramsdell, F., Brunkow, M. E., Ferguson, P. J., Whitesell, L., Kelly, T. E., Saulsbury, F. T., Chance, P. F. and Ochs, H. D.:The immune dysregulation, polyendocrinopathy, enteropathy, X-linked syndrome (IPEX) is caused by mutations of FOXP3. Nat. Genet., 27:20-21, 2001.
PubMed
18) Nishikawa, H. and Koyama, S.:Mechanisms of regulatory T cell infiltration in tumors:Implications for innovative immune precision therapies. J. Immunother. Cancer, 9:e002591, 2021.
PubMed
19) Shan, F., Somasundaram, A., Bruno, T. C., Workman, C. J. and Vignali, D. A. A.:Therapeutic targeting of regulatory T cells in cancer. Trends Cancer, 8:944-961, 2022.
PubMed
20) Saito, T., Nishikawa, H., Wada, H., Nagano, Y., Sugiyama, D., Atarashi, K., Maeda, Y., Hamaguchi, M., Ohkura, N., Sato, E., Nagase, H., Nishimura, J., Yamamoto, H., Takiguchi, S., Tanoue, T., Suda, W., Morita, H., Hattori, M., Honda, K., Mori, M., Doki, Y. and Sakaguchi, S.:Two FOXP3+CD4+ T cell subpopulations distinctly control the prognosis of colorectal cancers. Nat. Med., 22:679-684, 2016.
PubMed
21) Liu, W., Putnam, A. L., Xu-Yu, Z., Szot, G. L., Lee, M. R., Zhu, S., Gottlieb, P. A., Kapranov, P., Gingeras, T. R., Fazekas de St Groth, B., Clayberger, C., Soper, D. M., Ziegler, S. F. and Bluestone, J. A.:CD127 expression inversely correlates with Foxp3 and suppressive function of human CD4+ T reg cells. J. Exp. Med., 203:1701-1711, 2006.
 
22) Gooden, M. J., de Bock, G. H., Leffers, N., Daemen, T. and Nijman, H. W.:The prognostic influence of tumour-infiltrating lymphocytes in cancer:A systematic review with meta-analysis. Br. J. Cancer, 105:93-103, 2011.
 
23) Rech, A. J. and Vonderheide, R. H.:Clinical use of anti-CD25 antibody daclizumab to enhance immune responses to tumor antigen vaccination by targeting regulatory T cells. Ann. N. Y. Acad. Sci., 1174:99-106, 2009.
PubMed
24) Tay, C., Qian, Y. and Sakaguchi, S.:Hyper-progressive disease:The potential role and consequences of T-regulatory cells foiling anti-PD-1 cancer immunotherapy. Cancers, 13:48, 2020.
PubMed

[4] 免疫チェックポイント阻害薬の歴史と現状

P.27 掲載の参考文献
1) Schreiber, R. D., Old, L. J. and Smyth, M. J.:Cancer immunoediting:Integrating immunity's roles in cancer suppression and promotion. Science, 331:1565-1570, 2011.
PubMed
2) Wing, K., Onishi, Y., Prieto-Martin, P., Yamaguchi, T., Miyara, M., Fehervari, Z., Nomura, T. and Sakaguchi, S.:CTLA-4 control over Foxp3+ regulatory T cell function. Science, 322:271-275, 2008.
PubMed
3) Hodi, F. S., Bulter, M., Oble, D. A., Seiden, M. V., Haluska, F. G., Kruse, A., Macrae, S., Nelson, M., Canning, C., Lowy, I., Korman, A., Lautz, D., Russell, S., Jaklitsch, M. T., Ramaiya, N., Chen, T. C., Neuberg, D., Allison, J. P., Mihm, M. C. and Dranoff, G.:Immunologic and clinical effects of antibody blockade of cytotoxic T lymphocyte-associated antigen 4 in previously vaccinated cancer patients. Proc. Natl. Acad. Sci. U. S. A., 105:3005-3010, 2008.
 
4) Ishida, Y., Agata, Y., Shibahara, K. and Honjo, T.:Induced expression of PD-1, a novel member of the immunoglobulin gene superfamily, upon programmed cell death. EMBO J., 11:3887-3895, 1992.
PubMed
5) Antonia, S. J., Villegas, A., Daniel, D., Vicente, D., Murakami, S., Hui, R., Yokoi, T., Chiappori, A., Lee, K. H., de Wit, M., Cho, B. C., Bourhaba, M., Quantin, X., Tokito, T., Mekhail, T., Planchard, D., Kim, Y. C., Karapetis, C. S., Hiret, S., Ostoros, G., Kubota, K., Gray, J. E., Paz-Ares, L., de Castro Carpeno, J., Wadsworth, C., Melillo, G., Jiang, H., Huang, Y., Dennis, P. A. and Ozguroglu, M.;PACIFIC Investigators:Durvalumab after chemoradiotherapy in stage III non-small-cell lung cancer. N. Engl. J. Med., 377:1919-1929, 2017.
PubMed
6) Hodi, F. S., O'Day, S. J., McDermott, D. F., Weber, R. W., Sosman, J. A., Haanen, J. B., Gonzalez, R., Robert, C., Schadendorf, D., Hassel, J. C., Akerley, W., van den Eertwegh, A. J., Lutzky, J., Lorigan, P., Vaubel, J. M., Linette, G. P., Hogg, D., Ottensmeier, C. H., Lebbe, C., Peschel, C., Quirt, I., Clark, J. I., Wolchok, J. D., Weber, J. S., Tian, J., Yellin, M. J., Nichol, G. M., Hoos, A. and Urba, W. J.:Improved survival with ipilimumab in patients with metastatic melanoma. N. Engl. J. Med., 363:711-723, 2010.
PubMed

[5] 免疫チェックポイント阻害薬の将来

P.33 掲載の参考文献
1) Mellman, I., Coukos, G. and Dranoff, G.:Cancer immunotherapy comes of age. Nature, 480:480-489, 2011.
PubMed
2) Drake, C. G., Lipson, E. J. and Brahmer, J. R.:Breathing new life into immunotherapy:Review of melanoma, lung and kidney cancer. Nat. Rev. Clin. Oncol., 11:24-37, 2014.
PubMed
3) Borghaei, H., Paz-Ares, L., Horn, L., Spigel, D. R., Steins, M., Ready, N. E., Chow, L. Q., Vokes, E. E., Felip, E., Holgado, E., Barlesi, F., Kohlhaufl, M., Arrieta, O., Burgio, M. A., Fayette, J., Lena, H., Poddubskaya, E., Gerber, D. E., Gettinger, S. N., Rudin, C. M., Rizvi, N., Crino, L., Blumenschein, G. R. Jr., Antonia, S. J., Dorange, C., Harbison, C. T., Graf Finckenstein, F. and Brahmer, J. R.:Nivolumab versus docetaxel in advanced nonsquamous non-small-cell lung cancer. N. Engl. J. Med., 373:1627-1639, 2015.
PubMed
4) Kang, Y. K., Boku, N., Satoh, T., Ryu, M. H., Chao, Y., Kato, K., Chung, H. C., Chen, J. S., Muro, K., Kang, W. K., Yeh, K. H., Yoshikawa, T., Oh, S. C., Bai, L. Y., Tamura, T., Lee, K. W., Hamamoto, Y., Kim, J. G., Chin, K., Oh, D. Y., Minashi, K., Cho, J. Y., Tsuda, M. and Chen, L. T.:Nivolumab in patients with advanced gastric or gastro-oesophageal junction cancer refractory to, or intolerant of, at least two previous chemotherapy regimens (ONO-4538-12, ATTRACTION-2):A randomised, double-blind, placebocontrolled, phase 3 trial. Lancet, 390:2461-2471, 2017.
 
5) Robert, C., Long, G. V., Brady, B., Dutriaux, C., Maio, M., Mortier, L., Hassel, J. C., Rutkowski, P., McNeil, C., Kalinka-Warzocha, E., Savage, K. J., Hernberg, M. M., Lebbe, C., Charles, J., Mihalcioiu, C., Chiarion-Sileni, V., Mauch, C., Cognetti, F., Arance, A., Schmidt, H., Schadendorf, D., Gogas, H., Lundgren-Eriksson, L., Horak, C., Sharkey, B., Waxman, I. M., Atkinson, V. and Ascierto, P. A.:Nivolumab in previously untreated melanoma without BRAF mutation. N. Engl. J. Med., 372:320-330, 2015.
 
6) Schumacher, T. N. and Schreiber, R. D.:Neoantigens in cancer immunotherapy. Science, 348:69-74, 2015.
PubMed
7) Tumeh, P. C., Harview, C. L., Yearley, J. H., Shintaku, I. P., Taylor, E. J., Robert, L., Chmielowski, B., Spasic, M., Henry, G., Ciobanu, V., West, A. N., Carmona, M., Kivork, C., Seja, E., Cherry, G., Gutierrez, A. J., Grogan, T. R., Mateus, C., Tomasic, G., Glaspy, J. A., Emerson, R. O., Robins, H., Pierce, R. H., Elashoff, D. A., Robert, C. and Ribas, A.:PD-1 blockade induces responses by inhibiting adaptive immune resistance. Nature, 515:568-571, 2014.
PubMed
8) Riaz, N., Havel, J. J., Makarov, V., Desrichard, A., Urba, W. J., Sims, J. S., Hodi, F. S., Martin-Algarra, S., Mandal, R., Sharfman, W. H., Bhatia, S., Hwu, W. J., Gajewski, T. F., Slingluff, C. L. Jr., Chowell, D., Kendall, S. M., Chang, H., Shah, R., Kuo, F., Morris, L. G. T., Sidhom, J. W., Schneck, J. P., Horak, C. E., Weinhold, N. and Chan, T. A.:Tumor and microenvironment evolution during immunotherapy with nivolumab. Cell, 171:934-949, 2017.
 
9) Rizvi, N. A., Hellmann, M. D., Snyder, A., Kvistborg, P., Makarov, V., Havel, J. J., Lee, W., Yuan, J., Wong, P., Ho, T. S., Miller, M. L., Rekhtman, N., Moreira, A. L., Ibrahim, F., Bruggeman, C., Gasmi, B., Zappasodi, R., Maeda, Y., Sander, C., Garon, E. B., Merghoub, T., Wolchok, J. D., Schumacher, T. N. and Chan, T. A.:Cancer immunology:Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer. Science, 348:124-128, 2015.
 
10) Kono, K., Nakajima, S. and Mimura, K.:Current status of immune checkpoint inhibitors for gastric cancer. Gastric Cancer, 23:565-578, 2020.
PubMed
11) Janjigian, Y. Y., Shitara, K., Moehler, M., Garrido, M., Salman, P., Shen, L., Wyrwicz, L., Yamaguchi, K., Skoczylas, T., Campos Bragagnoli, A., Liu, T., Schenker, M., Yanez, P., Tehfe, M., Kowalyszyn, R., Karamouzis, M. V., Bruges, R., Zander, T., Pazo-Cid, R., Hitre, E., Feeney, K., Cleary, J. M., Poulart, V., Cullen, D., Lei, M., Xiao, H., Kondo, K., Li, M. and Ajani, J. A.:First-line nivolumab plus chemotherapy versus chemotherapy alone for advanced gastric, gastro-oesophageal junction, and oesophageal adenocarcinoma (CheckMate 649):A randomised, open-label, phase 3 trial. Lancet, 398:27-40, 2021.
PubMed
12) 日本胃癌学会編:胃癌治療ガイドライン医師用. 2021年7月改訂第6版, 金原出版, 東京, 2021.
 
13) Nakayama, Y., Mimura, K., Kua, L. F., Okayama, H., Min, A. K. T., Saito, K., Hanayama, H., Watanabe, Y., Saito, M., Momma, T., Saze, Z., Ohki, S., Suzuki, Y., Ichikawa, D., Yong, W. P. and Kono, K.:Immune suppression caused by PD-L2 expression on tumor cells in gastric cancer. Gastric Cancer, 23:961-973, 2020.
PubMed
14) Zhou, K. I., Peterson, B., Serritella, A., Thomas, J., Reizine, N., Moya, S., Tan, C., Wang, Y. and Catenacci, D. V. T.:Spatial and temporal heterogeneity of PD-L1 expression and tumor mutational burden in gastroesophageal adenocarcinoma at baseline diagnosis and after chemotherapy. Clin. Cancer Res., 26:6453-6463, 2020.
PubMed
15) Sahin, I. H., Zhang, J., Saridogan, T., Gorantla, V., Rhree, J., Malhotra, M., Thomas, R., Hsu, D. and Saeed, A.:Neoadjuvant immune checkpoint inhibitor therapy for patients with microsatellite instability-high colorectal cancer:Shedding light on the future. JCO Oncol. Pract., 19:251-259, 2023.
 
16) Mimura, K., The, J. L., Okayama, H., Shiraishi, K., Kua, L. F., Koh, V., Smoot, D. T., Ashktorab, H., Oike, T., Suzuki, Y., Fazreen, Z., Asuncion, B. R., Shabbir, A., Yong, W. P., So, J., Soong, R. and Kono, K.:PDL1 expression is mainly regulated by interferon gamma associated with JAK-STAT pathway in gastric cancer. Cancer Sci., 109:43-53, 2018.
 
17) Wolchok, J. D., Kluger, H., Callahan, M. K., Postow, M. A., Rizvi, N. A., Lesokhin, A. M., Segal, N. H., Ariyan, C. E., Gordon, R. A., Reed, K., Burke, M. M., Caldwell, A., Kronenberg, S. A., Agunwamba, B. U., Zhang, X., Lowy, I., Inzunza, H. D., Feely, W., Horak, C. E., Hong, Q., Korman, A. J., Wigginton, J. M., Gupta, A. and Sznol, M.:Nivolumab plus ipilimumab in advanced melanoma. N. Engl. J. Med., 369:122-133, 2013.
PubMed
18) Suzuki, Y., Mimura, K., Yoshimoto, Y., Watanabe, M., Ohkubo, Y., Izawa, S., Murata, K., Fujii, H., Nakano, T. and Kono, K.:Immunogenic tumor cell death induced by chemoradiotherapy in patients with esophageal squamous cell carcinoma. Cancer Res., 72:3967-3976, 2012.
PubMed
19) Postow, M. A., Callahan, M. K., Barker. C. A., Yamada, Y., Yuan, J., Kitano, S., Mu, Z., Rasalan, T., Adamow, M., Ritter, E., Sedrak, C., Jungbluth, A. A., Chua, R., Yang, A. S., Roman, R. A., Rosner, S., Benson, B., Allison, J. P., Lesokhin, A. M., Gnjatic, S. and Wolchok, J. D.:Immunologic correlates of the abscopal effect in a patient with melanoma. N. Engl. J. Med., 366:925-931, 2012.
 

[6] 肺がんから学ぶこと ; ガイドラインの変更

P.39 掲載の参考文献
1) 厚生労働省:人口動態調査. http://www.mhlw.go.jp/toukei/list/81-1.html
 
2) 日本肺癌学会編:肺癌取扱い規約. 第8版補訂版, 金原出版, 東京, 2021.
 
3) Brahmer, J., Reckamp, K. L., Baas, P., Crino, L., Eberhardt, W. E., Poddubskaya, E., Antonia, S., Pluzanski, A., Vokes, E. E., Holgado, E., Waterhouse, D., Ready, N., Gainor, J., Aren Frontera, O., Havel, L., Steins, M., Garassino, M. C., Aerts, J. G., Domine, M., Paz-Ares, L., Reck, M., Baudelet, C., Harbison, C. T., Lestini, B. and Spigel, D. R.:Nivolumab versus docetaxel in advanced squamous-cell non-small-cell lung cancer. N. Engl. J. Med., 373:123-135, 2015.
PubMed
4) Borghaei, H., Paz-Ares, L., Horn, L., Spigel, D. R., Steins, M., Ready, N. E., Chow, L. Q., Vokes, E. E., Felip, E., Holgado, E., Barlesi, F., Kohlhaufl, M., Arrieta, O., Burgio, M. A., Fayette, J., Lena, H., Poddubskaya, E., Gerber, D. E., Gettinger, S. N., Rudin, C. M., Rizvi, N., Crino, L., Blumenschein, G. R. Jr., Antonia, S. J., Dorange, C., Harbison, C. T., Graf Finckenstein, F. and Brahmer, J. R.:Nivolumab versus docetaxel in advanced nonsquamous non-small-cell lung cancer. N. Engl. J. Med., 373:1627-1639, 2015.
PubMed
5) Mok, T. S. K., Wu, Y. L., Kudaba, I., Kowalski, D. M., Cho, B. C., Turna, H. Z., Castro, G. Jr., Srimuninnimit, V., Laktionov, K. K., Bondarenko, I., Kubota, K., Lubiniecki, G. M., Zhang, J., Kush, D. and Lopes, G.;KEYNOTE-042 Investigators:Pembrolizumab versus chemotherapy for previously untreated, PD-L1-expressing, locally advanced or metastatic non-small-cell lung cancer (KEYNOTE-042):A randomised, open-label, controlled, phase 3 trial. Lancet, 393:1819-1830, 2019.
PubMed
6) Herbst, R. S., Giaccone, G., de Marinis, F., Reinmuth, N., Vergnenegre, A., Barrios, C. H., Morise, M., Felip, E., Andric, Z., Geater, S., Ozguroglu, M., Zou, W., Sandler, A., Enquist, I., Komatsubara, K., Deng, Y., Kuriki, H., Wen, X., McCleland, M., Mocci, S., Jassem, J. and Spigel, D. R.:Atezolizumab for first-line treatment of PD-L1-selected patients with NSCLC. N. Engl. J. Med., 383:1328-1339, 2020.
PubMed
7) 日本肺癌学会バイオマーカー委員会:肺癌患者におけるPD-L1検査の手引き. 第2版補遺, 2021. https://www.haigan.gr.jp/uploads/files/PD-L1%E6%A4%9C%E6%9F%BB%E3%81%AE%E6%89%8B%E5%BC%95%E3%81%8D%20%E8%A3%9C%E9%81%BA20210316.pdf
 
8) Hellmann, M. D., Paz-Ares, L., Bernabe Caro, R., Zurawski, B., Kim, S. W., Carcereny Costa, E., Park, K., Alexandru, A., Lupinacci, L., de la Mora Jimenez, E., Sakai, H., Albert, I., Vergnenegre, A., Peters, S., Syrigos, K., Barlesi, F., Reck, M., Borghaei, H., Brahmer, J. R., O'Byrne, K. J., Geese, W. J., Bhaga vatheeswaran, P., Rabindran, S. K., Kasinathan, R. S., Nathan, F. E. and Ramalingam, S. S.:Nivolumab plus ipilimumab in advanced non-small-cell lung cancer. N. Engl. J. Med., 381:2020-2031, 2019.
 
9) Paz-Ares, L., Ciuleanu, T. E., Cobo, M., Schenker, M., Zurawski, B., Menezes, J., Richardet, E., Bennouna, J., Felip, E., Juan-Vidal, O., Alexandru, A., Sakai, H., Lingua, A., Salman, P., Souquet, P. J., De Marchi, P., Martin, C., Perol, M., Scherpereel, A., Lu, S., John, T., Carbone, D. P., Meadows-Shropshire, S., Agrawal, S., Oukessou, A., Yan, J. and Reck, M.:First-line nivolumab plus ipilimumab combined with two cycles of chemotherapy in patients with non-small-cell lung cancer (CheckMate 9LA):An international, randomised, open-label, phase 3 trial. Lancet Oncol., 22:198-211, 2021.
PubMed
10) Hirsch, F. R., McElhinny, A., Stanforth, D., Ranger-Moore, J., Jansson, M., Kulangara, K., Richardson, W., Towne, P., Hanks, D., Vennapusa, B., Mistry, A., Kalamegham, R., Averbuch, S., Novotny, J., Rubin, E., Emancipator, K., McCaffery, I., Williams, J. A., Walker, J., Longshore, J., Tsao, M. S. and Kerr, K. M.:PD-L1 immunohistochemistry assays for lung cancer:Results from phase 1 of the blueprint PD-L1 IHC assay comparison project. J. Thorac. Oncol., 12:208-222, 2017.
PubMed
11) 日本肺癌学会編:EBMの手法による肺癌診療ガイドライン;悪性胸膜中皮腫・胸腺腫瘍含む. 2016年版, 第4版, 金原出版, 東京, 2016.
 
12) 日本肺癌学会編:肺癌診療ガイドライン;悪性胸膜中皮腫・胸腺腫瘍含む. 2022年版, 第7版, 金原出版, 東京, 2022.
 
13) アジレント・テクノロジー:PD-L1 IHC 22C3 pharmDx「ダコ」染色結果判定マニュアル, 2016.
 
14) Cho, J. H., Sorensen, S. F., Choi, Y. L., Feng, Y., Kim, T. E., Choi, H., Georgsen, J. B., Dolled-Filhart, M., Emancipator, K., Meldgaard, P., Sun, J. M., Kim, H. K., Choi, Y. S., Shim, Y. M., Zhou, W., Hager, H. and Kim, J.:Programmed death ligand 1 expression in paired non-small cell lung cancer tumor samples. Clin. Lung Cancer, 18:e473- e479, 2017.
 
15) Forde, P. M., Spicer, J., Lu, S., Provencio, M., Mitsudomi, T., Awad, M. M., Felip, E., Broderick, S. R., Brahmer, J. R., Swanson, S. J., Kerr, K., Wang, C., Ciuleanu, T. E., Saylors, G. B., Tanaka, F., Ito, H., Chen, K. N., Liberman, M., Vokes, E. E., Taube, J. M., Dorange, C., Cai, J., Fiore, J., Jarkowski, A., Balli, D., Sausen, M., Pandya, D., Calvet, C. Y. and Girard, N.;CheckMate 816 Investigators:Neoadjuvant nivolumab plus chemotherapy in resectable lung cancer. N. Engl. J. Med., 386:1973-1985, 2022.
PubMed
16) Horn, L., Spigel, D. R., Vokes, E. E., Holgado, E., Ready, N., Steins, M., Poddubskaya, E., Borghaei, H., Felip, E., Paz-Ares, L., Pluzanski, A., Reckamp, K. L., Burgio, M. A., Kohlhaeufl, M., Waterhouse, D., Barlesi, F., Antonia, S., Arrieta, O., Fayette, J., Crino, L., Rizvi, N., Reck, M., Hellmann, M. D., Geese, W. J., Li, A., Blackwood-Chirchir, A., Healey, D., Brahmer, J. and Eberhardt, W. E. E.:Nivolumab versus docetaxel in previously treated patients with advanced non-small-cell lung cancer:Two-year outcomes from two randomized, open-label, phase III trials (CheckMate 017 and CheckMate 057). J. Clin. Oncol., 35:3924-3933, 2017.
PubMed

[7] 化学療法と免疫療法

P.45 掲載の参考文献
1) Small, E. J., Schellhammer, P. F., Higano, C. S., Redfern, C. H., Nemunaitis, J. J., Valone, F. H., Verjee, S. S., Jones, L. A. and Hershberg, R. M.:Placebo-controlled phase III trial of immunologic therapy with sipuleucel-T (APC8015) in patients with metastatic, asymptomatic hormone refractory prostate cancer. J. Clin. Oncol., 24:3089-3094, 2006.
PubMed
2) Bauer, C., Kuhnemuth, B., Duewell, P., Ormann, S., Gress, T. and Schnurr, M.:Prevailing over T cell exhaustion:New developments in the immunotherapy of pancreatic cancer. Cancer Lett., 381:259-268, 2016.
 
3) Onishi, H., Morisaki, T., Kiyota, A., Koya, N., Tanaka, H., Umebayashi, M. and Katano, M.:The Hedgehog inhibitor cyclopamine impairs the benefits of immunotherapy with activated T and NK lymphocytes derived from patients with advanced cancer. Cancer Immunol. Immunother., 62:1029-1039, 2013.
PubMed
4) Onishi, H., Morisaki, T., Kiyota, A., Koya, N., Tanaka, H., Umebayashi, M. and Katano, M.:The Hedgehog inhibitor suppresses the function of monocyte-derived dendritic cells from patients with advanced cancer under hypoxia. Biochem. Biophys. Res. Commun., 436:53-59, 2013.
PubMed
5) Morisaki, T., Onishi, H. and Katano, M.:Cancer immunotherapy using NKG2D and DNAM-1 systems. Anticancer Res., 32:2241-2247, 2012.
PubMed
6) Morisaki, T., Hirano, T., Koya, N., Kiyota, A., Tanaka, H., Umebayashi, M., Onishi, H. and Katano, M.:NKG2D-directed cytokine-activated killer lymphocyte therapy combined with gemcitabine for patients with chemoresistant metastatic solid tumors. Anticancer Res., 34:4529-4538, 2014.
PubMed
7) Todaro, M., D'Asaro, M., Caccamo, N., Iovino, F., Francipane, M. G., Meraviglia, S., Oriando, V., La Mendola, C., Gulotta, G., Salerno, A., Dieli, F. and Stassi, G.:Efficient killing of human colon cancer stem cells by gammadelta T lymphocytes. J. Immunol., 182:7287-7296, 2009.
 
8) Shafer, M., Cruz, C. R., Leen, A. M., Ku, S., Lu, A., Rousseau, A., Heslop, H. E., Rooney, C. M., Bollard, C. M. and Foster, A. E.:Antigen-specific cytotoxic T lymphocytes can target chemoresistant side-population tumor cells in Hodgkin lymphoma. Leuk. Lymphoma, 51:870-880, 2010.
 
9) Gammaitoni, L., Giraudo, L., Leuci, V., Todorovic, M., Mesiano, G., Picciotto, F., Pisacane, A., Zaccagna, A., Volpe, M. G., Gallo, S., Caravelli, D., Giacone, E., Venesio, T., Balsamo, A., Pignochino, Y., Grignani, G., Carnevale-Schianca, F., Aglietta, M. and Sangiolo, D.:Effective activity of cytokine-induced killer cells against autologous metastatic melanoma including cells with stemness features. Clin. Cancer Res., 19:4347-4358, 2013.
 
10) Ames, E., Canter, R. J., Grossenbacher, S. K., Mac, C., Chen, M., Smith, R. C., Hagino, T., Perez-Cunningham, J., Sckisel, G. D., Urayama, S., Monjazeb, A. M., Fragoso, R. C., Sayers, T. J. and Murphy, W. J.:NK cells preferentially target tumor cells with a cancer stem cell phenotype. J. Immunol., 195:4010-4019, 2015.
 
11) Shibutani, S., Inoue, F., Aramaki, O., Akiyama, Y., Matsumoto, K., Shimazu, M., Kitajima, M., Ikeda, Y., Shirasugi, N. and Niimi, M.:Effects of immunosuppressants on induction of regulatory cells after intratracheal delivery of alloantigen. Transplantation, 79:904-913, 2005.
PubMed
12) Kawai, M., Kitade, H., Mathieu, C., Wear, M. and Pirenne, J.:Inhibitory and stimulatory effects of cyclosporine A on the development of regulatory T-cells in vivo. Transplantation, 79:1073-1077, 2005.
 
13) Lutsiak, M. E., Semnari, R. T., De Pascalis, R., Kashmiri, S. V., Schlom, J. and Sabzevari, H.:Inhibition of CD4+25+ T-regulatory cell function implicated in enhanced immune response by low-dose cyclophosphamide. Blood, 105:2862-2868, 2005.
 
14) 森崎隆:免疫療法と化学療法併用による総合的癌治療;その理論と実際. Biotherapy, 23:295-301, 2009.
Medical*Online
15) Larmonier, N., Janikashvili, N., LaCasse, C. J., Larmonier, C. B., Cantrell, J., Situ, E., Lundeen, T., Bonnotte, B. and Katsanis, E.:Imatinib mesylate inhibits CD4+ CD25+ regulatory T cell activity and enhances active immunotherapy against BCR-ABL-tumors. J. Immunol., 181:6955-6963, 2008.
PubMed
16) Fei, F., Yu, Y., Schmitt, A., Rojewski, M. T., Chen, B., Gotz, M., Dohner, H., Bunjes, D. and Schmitt, M.:Dasatinib inhibits the proliferation and function of CD4+ CD25+ regulatory T cells. Br. J. Haematol., 144:195-205, 2009.
 
17) Apetoh, L., Ghiringhelli, F., Tesniere, A., Obeid, M., Ortiz, C., Criollo, A., Mignot, G., Maiuri, M. C., Ullrich, E., Saulnier, P., Yang, H., Amigorena, S., Ryffel, B., Barrat, F. J., Satfig, P., Levi, F., Lidereau, R., Nogues, C., Mira, J. P., Chompret, A., Joulin, V., Clavel-Chapelon, F., Bourhis, J., Andre, F., Delaloge, S., Tursz, T., Kroemer, G. and Zitvogel, L.:Toll-like receptor 4-dependent contribution of the immune system to anticancer chemotherapy and radiotherapy. Nat. Med., 13:1050-1059, 2007.
 
18) Galluzzi, L., Buque, A., Kepp, O., Zitvogel, L. and Kroemer, G.:Immunogenic cell death in cancer and infectious disease. Nat. Rev. Immunol., 17:97-111, 2017.
PubMed
19) Martins, I., Wang, Y., Michaud, M., Ma, Y., Sukkurwala, A. Q., Shen, S., Kepp, O., Metivier, D., Galluzzi, L., Perfettini, J. L., Zitvogel, L. and Kroemer, G.:Molecular mechanisms of ATP secretion during immunogenic cell death. Cell Death Differ., 21:79-91, 2014.
PubMed
20) Garg, A. D., More, S., Rufo, N., Mece, O., Sassano, M. L., Agostinis, P., Zitvogel, L., Kroemer, G. and Galluzzi, L.:Trial watch:Immunogenic cell death induction by anticancer chemotherapeutics. Oncoimmunology, 6:e1386829, 2017.
PubMed
21) Dwary, A. D., Master, S., Patel, A., Cole, C., Mansour, R., Mills, G., Koshy, N., Peddi, P., Burton, G., Hammoud, D. and Beedupalli, K.:Excellent response to chemotherapy post immunotherapy. Oncotarget, 8:91795-91802, 2017.
PubMed
22) Dudley, M. E., Wunderlich, J. R., Yang, J. C., Sherry, R. M., Topalian, S. L., Restifo, N. P., Royal, R. E., Kammula, U., White, D. E., Mavroukakis, S. A., Rogers, L. J., Gracia, G. J., Jones, S. A., Mangiameli, D. P., Pelletier, M. M., Gea-Banacloche, J., Robinson, M. R., Berman, D. M., Filie, A. C., Abati, A. and Rosenberg, S. A.:Adoptive cell transfer therapy following non-myeloablative but lymphodepleting chemotherapy for the treatment of patients with refractory metastatic melanoma. J. Clin. Oncol., 23:2346-2357, 2005.
PubMed
23) Shimizu, K., Kotera, Y., Aruga, A., Takeshita, N., Katagiri, S., Ariizumi, S., Takahashi, Y., Yoshitoshi, K., Takasaki, K. and Yamamoto, M.:Postoperative dendritic cell vaccine plus activated T-cell transfer improves the survival of patients with invasive hepatocellular carcinoma. Hum. Vaccin. Immunother., 10:970-976, 2014.
 

[8] BRM療法とサイトカイン療法

P.49 掲載の参考文献
1) Oldham, R. K.:Biological response modifiers programme and cancer chemotherapy. Int. J. Tissue React., 4:173-188, 1982.
PubMed
2) 山口佳之, 山村真弘, 弘中克治, 岡脇誠:バイオセラピィの息吹;カワラタケが拓いた世界. Biotherapy, 25:785-790, 2011.
Medical*Online
3) Nakazato, H., Koike, A., Saji, S., Ogawa, N. and Sakamoto, J.:Efficacy of immunochemotherapy as adjuvant treatment after curative resection of gastric cancer:Study Group of Immunochemotherapy with PSK for gastric cancer. Lancet, 343:1122-1126, 1994.
 
4) Taniguchi, T., Matsui, H., Fujita, T., Takaoka, C., Kashima, N., Yoshimoto, R. and Hamuro, J.:Structure and expression of a cloned cDNA for human interleukin-2. Nature, 302:305-310, 1983.
PubMed
5) Ohno, R., Yamaguchi, Y., Toge, T., Kinouchi, T., Kotake, T., Shibata, M., Kiyohara, Y., Ikeda, S., Fukui, I., Gohchi, A., Sugiyama, Y., Saji, S., Hazama, S., Oka, M., Ohnishi, K., Ohhashi, Y., Tsukagoshi, S. and Taguchi, T.:A dose-escalation and pharmacokinetic study of subcutaneously administered recombinant human interleukin 12 and its biological effects in Japanese patients with advanced malignancies. Clin. Cancer Res., 6:2661-2669, 2000.
PubMed
6) Yamaguchi, Y., Miyahara, E., Ohshita, A., Kawabuchi, Y., Ohta, K., Shimizu, K., Minami, K., Hihara, J., Sawamura, A. and Toge, T.:Locoregional immunotherapy of malignant effusion from colorectal cancer using the streptococcal preparation OK-432 plus interleukin-2:Induction of autologous tumor-reactive CD4+ Th1 killer lymphocytes. Br. J. Cancer, 89:1876-1884, 2003.
PubMed
7) Chen, D. S. and Mellman, I.:Elements of cancer immunity and the cancer-immune set point. Nature, 541:321-330, 2017.
PubMed
8) Sun, Z., Ren, Z., Yang, K., Liu, Z., Cao, S., Deng, S., Xu, L., Liang, Y., Guo, J., Bian, Y., Xu, H., Shi, J., Wang, F., Fu, Y. X. and Peng, H.:A next-generation tumor-targeting IL-2 preferentially promotes tumor-infiltrating CD8+ T-cell response and effective tumor control. Nat. Commun., 10:3874, 2019.
 

[9] 樹状細胞ワクチンとペプチドワクチン療法

P.55 掲載の参考文献
1) Sharma, P. and Allison, J. P.:Immune checkpoint targeting in cancer therapy:Toward combination strategies with curative potential. Cell, 161:205-214, 2015.
PubMed
2) Maude, S. L., Frey, N., Shaw, P. A., Aplenc, R., Barrett, D. M., Bunin, N. J., Chew, A., Gonzalez, V. E., Zheng, Z., Lacey, S. F., Mahnke, Y. D., Melenhorst, J. J., Rheingold, S. R., Shen, A., Teachey, D. T., Levine, B. L., June, C. H., Porter, D. L. and Grupp, S. A.:Chimeric antigen receptor T cells for sustained remissions in leukemia. N. Engl. J. Med., 371:1507-1517, 2014.
PubMed
3) Ramachandran, M., Dimberg, A. and Essand, M.:The cancer-immunity cycle as rational design for synthetic cancer drugs:Novel DC vaccines and CAR T-cells. Semin. Cancer Biol., 45:23-35, 2017.
 
4) Kantoff, P. W., Higano, C. S., Shore, N. D., Berger, E. R., Small, E. J., Penson, D. F., Redfern, C. H., Ferrari, A. C., Dreicer, R., Sims, R. B., Xu, Y., Frohlich, M. W. and Schellhammer, P. F.:Sipuleucel-T immunotherapy for castration-resistant prostate cancer. N. Engl. J. Med., 363:411-422, 2010.
PubMed
5) Melero, I., Gaudernack, G., Gerritsen, W., Huber, C., Parmiani, G., Scholl, S., Thatcher, N., Wagstaff, J., Zielinski, C., Faulkner, I. and Mellstedt, H.:Therapeutic vaccines for cancer:An overview of clinical trials. Nat. Rev. Clin. Oncol., 11:509-524, 2014.
PubMed
6) Okabe, H., Satoh, S., Kato, T., Kitahara, O., Yanagawa, R., Yamaoka, Y., Tsunoda, T., Furukawa, Y. and Nakamura, Y.:Genome-wide analysis of gene expression in human hepatocellular carcinomas using cDNA microarray:Identification of genes involved in viral carcinogenesis and tumor progression. Cancer Res., 61:2129-2137, 2001.
PubMed
7) Chiarle, R., Martinengo, C., Mastini, C., Ambrogio, C., D'Escamard, V., Forni, G. and Inghirami, G.:The anaplastic lymphoma kinase is an effective oncoantigen for lymphoma vaccination. Nat. Med., 14:676-680, 2008.
PubMed
8) Mastini, C., Martinengo, C., Inghirami, G. and Chiarle, R.:Anaplastic lymphoma kinase:An oncogene for tumor vaccination. J. Mol. Med., 87:669-677, 2009.
PubMed
9) Osawa, R., Tsunoda, T., Yoshimura, S., Watanabe, T., Miyazawa, M., Tani, M., Takeda, K., Nakagawa, H., Nakamura, Y. and Yamaue, H.:Identification of HLA-A24-restricted novel T cell epitope peptides derived from P-cadherin and kinesin family member 20A. J. Biomed. Biotechnol., 2012:848042, 2012.
 
10) Suda, T., Tsunoda, T., Daigo, Y., Nakamura, Y. and Tahara, H.:Identification of human leukocyte antigen-A24-restricted epitope peptides derived from gene products upregulated in lung and esophageal cancers as novel targets for immunotherapy. Cancer Sci., 98:1803-1808, 2007.
PubMed
11) Kanehira, M., Harada, Y., Takata, R., Shuin, T., Miki, T., Fujioka, T., Nakamura, Y. and Katagiri, T.:Involvement of upregulation of DEPDC1 (DEP domain containing 1) in bladder carcinogenesis. Oncogene, 26:6448-6455, 2007.
PubMed
12) Yokomine, K., Senju, S., Nakatsura, T., Irie, A., Hayashida, Y., Ikuta, Y., Harao, M., Imai, K., Baba, H., Iwase, H., Nomori, H., Takahashi, K., Daigo, Y., Tsunoda, T., Nakamura, Y., Sasaki, Y. and Nishimura, Y.:The forkhead box M1 transcription factor as a candidate of target for anti-cancer immunotherapy. Int. J. Cancer, 126:2153-2163, 2010.
PubMed
13) Harao, M., Hirata, S., Irie, A., Senju, S., Nakatsura, T., Komori, H., Ikuta, Y., Yokomine, K., Imai, K., Inoue, M., Harada, K., Mori, T., Tsunoda, T., Nakatsuru, S., Daigo, Y., Nomori, H., Nakamura, Y., Baba, H. and Nishimura, Y.:HLA-A2-restricted CTL epitopes of a novel lung cancer-associated cancer testis antigen, cell division cycle associated 1, can induce tumor-reactive CTL. Int. J. Cancer, 123:2616-2625, 2008.
PubMed
14) Imai, K., Hirata, S., Irie, A., Senju, S., Ikuta, Y., Yokomine, K., Harao, M., Inoue, M., Tsunoda, T., Nakatsuru, S., Nakagawa, H., Nakamura, Y., Baba, H. and Nishimura, Y.:Identification of a novel tumor-associated antigen, cadherin 3/P-cadherin, as a possible target for immunotherapy of pancreatic, gastric, and colorectal cancers. Clin. Cancer Res., 14:6487-6495, 2008.
PubMed
15) Tomita, Y., Harao, M., Senju, S., Imai, K., Hirata, S., Irie, A., Inoue, M., Hayashida, Y., Yoshimoto, K., Shiraishi, K., Mori, T., Nomori, H., Kohrogi, H. and Nishimura, Y.:Peptides derived from human insulin-like growth factor-II mRNA binding protein 3 can induce human leukocyte antigen-A2-restricted cytotoxic T lymphocytes reactive to cancer cells. Cancer Sci., 102:71-78, 2011.
PubMed
16) Asahara, S., Takeda, K., Yamao, K., Maguchi, H. and Yamaue, H.:Phase I/II clinical trial using HLA-A24-restricted peptide vaccine derived from KIF20A for patients with advanced pancreatic cancer. J. Transl. Med., 11:291, 2013.
PubMed
17) Iwahashi, M., Katsuda, M., Nakamori, M., Nakamura, M., Naka, T., Ojima, T., Iida, T. and Yamaue, H.:Vaccination with peptides derived from cancer-testis antigens in combination with CpG-7909 elicits strong specific CD8+ T cell response in patients with metastatic esophageal squamous cell carcinoma. Cancer Sci., 101:2510-2517, 2010.
PubMed
18) Yoshitake, Y., Fukuma, D., Yuno, A., Hirayama, M., Nakayama, H., Tanaka, T., Nagata, M., Takamune, Y., Kawahara, K., Nakagawa, Y., Yoshida, R., Hirosue, A., Ogi, H., Hiraki, A., Jono, H., Hamada, A., Yoshida, K., Nishimura, Y., Nakamura, Y. and Shinohara, M.:Phase II clinical trial of multiple peptide vaccination for advanced head and neck cancer patients revealed induction of immune responses and improved OS. Clin. Cancer Res., 21:312-321, 2015.
PubMed
19) Cheever, M. A., Allison, J. P., Ferris, A. S., Finn, O. J., Hastings, B. M., Hecht, T. T., Mellman, I., Prindiville, S. A., Viner, J. L., Weiner, L. M. and Matrisian, L. M.:The prioritization of cancer antigens:A national cancer institute pilot project for the acceleration of translational research. Clin. Cancer Res., 15:5323-5337, 2009.
PubMed
20) Sugiyama, H.:WT1 (Wilms' tumor gene 1):Biology and cancer immunotherapy. Jpn. J. Clin. Oncol., 40:377-387, 2010.
PubMed
21) Miyatake, T., Ueda, Y., Morimoto, A., Enomoto, T., Nishida, S., Shirakata, T., Oka, Y., Tsuboi, A., Oji, Y., Hosen, N., Nakatsuka, S., Morita, S., Sakamoto, J., Sugiyama, H. and Kimura, T.:WT1 peptide immunotherapy for gynecologic malignancies resistant to conventional therapies:A phase II trial. J. Cancer Res. Clin. Oncol., 139:457-463, 2013.
PubMed
22) Oji, Y., Hashimoto, N., Tsuboi, A., Murakami, Y., Iwai, M., Kagawa, N., Chiba, Y., Izumoto, S., Elisseeva, O., Ichinohasama, R., Sakamoto, J., Morita, S., Nakajima, H., Takashima, S., Nakae, Y., Nakata, J., Kawakami, M., Nishida, S., Hosen, N., Fujiki, F., Morimoto, S., Adachi, M., Iwamoto, M., Oka, Y., Yoshimine, T. and Sugiyama, H.:Association of WT1 IgG antibody against WT1 peptide with prolonged survival in glioblastoma multiforme patients vaccinated with WT1 peptide. Int. J. Cancer, 139:1391-1401, 2016.
PubMed
23) Folkman, J.:Tumor angiogenesis:Therapeutic implications. N. Engl. J. Med., 285:1182-1186, 1971.
PubMed
24) Ishizaki, H., Tsunoda, T., Wada, S., Yamauchi, M., Shibuya, M. and Tahara, H.:Inhibition of tumor growth with antiangiogenic cancer vaccine using epitope peptides derived from human vascular endothelial growth factor receptor 1. Clin. Cancer Res., 12:5841-5849, 2006.
PubMed
25) Wada, S., Tsunoda, T., Baba, T., Primus, F. J., Kuwano, H., Shibuya, M. and Tahara, H.:Rationale for antiangiogenic cancer therapy with vaccination using epitope peptides derived from human vascular endothelial growth factor receptor 2. Cancer Res., 65:4939-4946, 2005.
PubMed
26) Miyazawa, M., Ohsawa, R., Tsunoda, T., Hirono, S., Kawai, M., Tani, M., Nakamura, Y. and Yamaue, H.:Phase I clinical trial using peptide vaccine for human vascular endothelial growth factor receptor 2 in combination with gemcitabine for patients with advanced pancreatic cancer. Cancer Sci., 101:433-439, 2010.
PubMed
27) Yamaue, H., Tsunoda, T., Tani, M., Miyazawa, M., Yamao, K., Mizuno, N., Okusaka, T., Ueno, H., Boku, N., Fukutomi, A., Ishii, H., Ohkawa, S., Furukawa, M., Maguchi, H., Ikeda, M., Togashi, Y., Nishio, K. and Ohashi, Y.:Randomized phase II/III clinical trial of elpamotide for patients with advanced pancreatic cancer:PEGASUS-PC Study. Cancer Sci., 106:883-890, 2015.
PubMed
28) Middleton, G., Silcocks, P., Cox, T., Valle, J., Wadsley, J., Propper, D., Coxon, F., Ross, P., Madhusudan, S., Roques, T., Cunningham, D., Falk, S., Wadd, N., Harrison, M., Corrie, P., Iveson, T., Robinson, A., McAdam, K., Eatock, M., Evans, J., Archer, C., Hickish, T., Garcia-Alonso, A., Nicolson, M., Steward, W., Anthoney, A., Greenhalf, W., Shaw, V., Costello, E., Naisbitt, D., Rawcliffe, C., Nanson, G. and Neoptolemos, J.:Gemcitabine and capecitabine with or without telomerase peptide vaccine GV1001 in patients with locally advanced or metastatic pancreatic cancer (TeloVac):An open-label, randomised, phase 3 trial. Lancet Oncol., 15:829-840, 2014.
 
29) Butts, C., Socinski, M. A., Mitchell, P. L., Thatcher, N., Havel, L., Krzakowski, M., Nawrocki, S., Ciuleanu, T. E., Bosquee, L., Trigo, J. M., Spira, A., Tremblay, L., Nyman, J., Ramlau, R., Wickart-Johansson, G., Ellis, P., Gladkov, O., Pereira, J. R., Eberhardt, W. E., Helwig, C., Schroder, A. and Shepherd, F. A.;START trial team:Tecemotide (L-BLP25) versus placebo after chemoradiotherapy for stage III nonsmall-cell lung cancer (START):A randomised, double-blind, phase 3 trial. Lancet Oncol., 15:59-68, 2014.
 
30) Schuster, J., Lai, R. K., Recht, L. D., Reardon, D. A., Paleologos, N. A., Groves, M. D., Mrugala, M. M., Jensen, R., Baehring, J. M., Sloan, A., Archer, G. E., Bigner, D. D., Cruickshank, S., Green, J. A., Keler, T., Davis, T. A., Heimberger, A. B. and Sampson, J. H.:A phase II, multicenter trial of rindopepimut (CDX-110) in newly diagnosed glioblastoma:The ACT III study. Neuro Oncol., 17:854-861, 2015.
PubMed
31) Stone, J. D., Harris, D. T. and Kranz, D. M.:TCR affinity for p/MHC formed by tumor antigens that are self-proteins:Impact on efficacy and toxicity. Curr. Opin. Immunol., 33:16-22, 2015.
PubMed
32) Deng, X. and Nakamura, Y.:Cancer precision medicine:From cancer screening to drug selection and personalized immunotherapy. Trends Pharmacol. Sci., 38:15-24, 2017.
PubMed
33) Carreno, B. M., Magrini, V., Becker-Hapak, M., Kaabinejadian, S., Hundal, J., Petti, A. A., Ly, A., Lie, W. R., Hildebrand, W. H., Mardis, E. R. and Linette, G. P.:Cancer immunotherapy:A dendritic cell vaccine increases the breadth and diversity of melanoma neoantigen-specific T cells. Science, 348:803-808, 2015.
PubMed
34) Kranz, L. M., Diken, M., Haas, H., Kreiter, S., Loquai, C., Reuter, K. C., Meng, M., Fritz, D., Vascotto, F., Hefesha, H., Grunwitz, C., Vormehr, M., Husemann, Y., Selmi, A., Kuhn, A. N., Buck, J., Derhovanessian, E., Rae, R., Attig, S., Diekmann, J., Jabulowsky, R. A., Heesch, S., Hassel, J., Langguth, P., Grabbe, S., Huber, C., Tureci, O. and Sahin, U.:Systemic RNA delivery to dendritic cells exploits antiviral defence for cancer immunotherapy. Nature, 534:396-401, 2016.
PubMed
35) Yang, A., Farmer, E., Wu, T. C. and Hung, C. F.:Perspectives for therapeutic HPV vaccine development. J. Biomed. Sci., 23:75, 2016.
 
36) Lee, J. H., Lee, J. H., Lim, Y. S., Yeon, J. E., Song, T. J., Yu, S. J., Gwak, G. Y., Kim, K. M., Kim, Y. J., Lee, J. W. and Yoon, J. H.:Adjuvant immunotherapy with autologous cytokine-induced killer cells for hepatocellular carcinoma. Gastroenterology, 148:1383-1391, e1386, 2015.
 
37) Eggermont, A. M., Chiarion-Sileni, V., Grob, J. J., Dummer, R., Wolchok, J. D., Schmidt, H., Hamid, O., Robert, C., Ascierto, P. A., Richards, J. M., Lebbe, C., Ferraresi, V., Smylie, M., Weber, J. S., Maio, M., Konto, C., Hoos, A., de Pril, V., Gurunath, R. K., de Schaetzen, G., Suciu, S. and Testori, A.:Adjuvant ipilimumab versus placebo after complete resection of high-risk stage III melanoma (EORTC 18071):A randomised, double-blind, phase 3 trial. Lancet Oncol., 16:522-530, 2015.
PubMed
38) Miyazawa, M., Katsuda, M., Maguchi, H., Katanuma, A., Ishii, H., Ozaka, M., Yamao, K., Imaoka, H., Kawai, M., Hirono, S., Okada, K. I. and Yamaue, H.:Phase II clinical trial using novel peptide cocktail vaccine as a postoperative adjuvant treatment for surgically resected pancreatic cancer patients. Int. J. Cancer, 140:973-982, 2017.
PubMed
39) Katsuda, M., Iwahashi, M., Matsuda, K., Miyazawa, M., Nakamori, M., Nakamura, M., Ojima, T., Iida, T., Hayata, K. and Yamaue, H.:Comparison of different classes of CpG-ODN in augmenting the generation of human epitope peptide-specific CTLs. Int. J. Oncol., 39:1295-1302, 2011.
PubMed
40) Kimura, Y., Tsukada, J., Tomoda, T., Takahashi, H., Imai, K., Shimamura, K., Sunamura, M., Yonemitsu, Y., Shimodaira, S., Koido, S., Homma, S. and Okamoto, M.:Clinical and immunologic evaluation of dendritic cell-based immunotherapy in combination with gemcitabine and/or S-1 in patients with advanced pancreatic carcinoma. Pancreas, 41:195-205, 2012.
PubMed
41) Kobayashi, M., Shimodaira, S., Nagai, K., Ogasawara, M., Takahashi, H., Abe, H., Tanii, M., Okamoto, M., Tsujitani, S., Yusa, S., Ishidao, T., Kishimoto, J., Shibamoto, Y., Nagaya, M. and Yonemitsu, Y.:Prognostic factors related to add-on dendritic cell vaccines on patients with inoperable pancreatic cancer receiving chemotherapy:A multicenter analysis. Cancer Immunol. Immunother., 63:797-806, 2014.
PubMed
42) Mayanagi, S., Kitago, M., Sakurai, T., Matsuda, T., Fujita, T., Higuchi, H., Taguchi, J., Takeuchi, H., Itano, O., Aiura, K., Hamamoto, Y., Takaishi, H., Okamoto, M., Sunamura, M., Kawakami, Y. and Kitagawa, Y.:Phase I pilot study of Wilms tumor gene 1 peptide-pulsed dendritic cell vaccination combined with gemcitabine in pancreatic cancer. Cancer Sci., 106:397-406, 2015.
PubMed
43) Koido, S., Homma, S., Okamoto, M., Takakura, K., Mori, M., Yoshizaki, S., Tsukinaga, S., Odahara, S., Koyama, S., Imazu, H., Uchiyama, K., Kajihara, M., Arakawa, H., Misawa, T., Toyama, Y., Yanagisawa, S., Ikegami, M., Kan, S., Hayashi, K., Komita, H., Kamata, Y., Ito, M., Ishidao, T., Yusa, S., Shimodaira, S., Gong, J., Sugiyama, H., Ohkusa, T. and Tajiri, H.:Treatment with chemotherapy and dendritic cells pulsed with multiple Wilms' tumor 1 (WT1)-specific MHC class I/II-restricted epitopes for pancreatic cancer. Clin. Cancer Res., 20:4228-4239, 2014.
PubMed

[10] 消化器がんに対するがん免疫療法の臨床試験と抑制性免疫の解析

P.63 掲載の参考文献
1) Hazama, S., Tamada, K., Yamaguchi, Y., Kawakami, Y. and Nagano, H.:Current status of immunotherapy against gastrointestinal cancers and its biomarkers:Perspective for precision immunotherapy. Ann. Gastroenterol. Surg., 2:289-303, 2018.
PubMed
2) van der Bruggen, P., Traversari, C., Chomez, P., Lurquin, C., De Plaen, E., Van den Eynde, B., Knuth, A. and Boon, T.:A gene encoding an antigen recognized by cytolytic T lymphocytes on a human melanoma. Science, 254:1643-1647, 1991.
 
3) Hazama, S., Nakamura, Y., Takenouchi, H., Suzuki, N., Tsunedomi, R., Inoue, Y., Tokuhisa, Y., Iizuka, N., Yoshino, S., Takeda, K., Shinozaki, H., Kamiya, A., Furukawa, H. and Oka, M.:A phase I study of combination vaccine treatment of five therapeutic epitope-peptides for metastatic colorectal cancer:Safety, immunological response, and clinical outcome. J. Transl. Med., 12:63, 2014.
 
4) Hazama, S., Takenouchi, H., Tsunedomi, R., Iida, M., Suzuki, N., Iizuka, N., Inoue, Y., Sakamoto, K., Nakao, M., Shindo, Y., Kanekiyo, S., Tokumitsu, Y., Yoshimura, K., Maeda, N., Maeda, K., Maeda, Y., Matsui, H., Yoshino, S., Nakamura, Y., Fujita, Y., Hamamoto, Y., Okamoto, M., Fujita, T., Kawakami, Y. and Oka, M.:Predictive biomarkers for the outcome of vaccination of five therapeutic epitope peptides for colorectal cancer. Anticancer Res., 34:4201-4205, 2014.
PubMed
5) Hazama, S., Nakamura, Y., Tanaka, H., Hirakawa, K., Tahara, K., Shimizu, R., Ozasa, H., Etoh, R., Sugiura, F., Okuno, K., Furuya, T., Nishimura, T., Sakata, K., Yoshimatsu, K., Takenouchi, H., Tsunedomi, R., Inoue, Y., Kanekiyo, S., Shindo, Y., Suzuki, N., Yoshino, S., Shinozaki, H., Kamiya, A., Furukawa, H., Yamanaka, T., Fujita, T., Kawakami, Y. and Oka, M.:A phase II study of five peptides combination with oxaliplatin-based chemotherapy as a first-line therapy for advanced colorectal cancer (FXV study). J. Transl. Med., 12:108, 2014.
 
6) Yamada, K., Hazama, S., Suzuki, N., Xu, M., Nakagami, Y., Fujiwara, N., Tsunedomi, R., Yoshida, S., Tomochika, S., Matsukuma, S., Matsui, H., Tokumitsu, Y., Kanekiyo, S., Shindo, Y., Watanabe, Y., Iida, M., Takeda, S., Ioka, T., Ueno, T., Ogihara, H., Hamamoto, Y., Hoshii, Y., Kawano, H., Fujita, T., Kawakami, Y. and Nagano, H.:Siglec-7 is a predictive biomarker for the efficacy of cancer vaccination against metastatic colorectal cancer. Oncol. Lett., 21:10, 2021.
PubMed
7) Yaguchi, T. and Kawakami, Y.:Cancer-induced heterogeneous immunosuppressive tumor microenvironments and their personalized modulation. Int. Immunol., 28:393-399, 2016.
PubMed
8) Finn, R. S., Qin, S., Ikeda, M., Galle, P. R., Ducreux, M., Kim, T. Y., Kudo, M., Breder, V., Merle, P., Kaseb, A. O., Li, D., Verret, W., Xu, D. Z., Hernandez, S., Liu, J., Huang, C., Mulla, S., Wang, Y., Lim, H. Y., Zhu, A. X. and Cheng, A. L.;IMbrave150 Investigators:Atezolizumab plus bevacizumab in unresectable hepatocellular carcinoma. N. Engl. J. Med., 382:1894-1905, 2020.
PubMed
9) 日本肝臓学会編:肝癌診療ガイドライン. 2021年版, 第5版, 金原出版, 東京, 2021.
 
10) Huang, A. C., Postow, M. A., Orlowski, R. J., Mick, R., Bengsch, B., Manne, S., Xu, W., Harmon, S., Giles, J. R., Wenz, B., Adamow, M., Kuk, D., Panageas, K. S., Carrera, C., Wong, P., Quagliarello, F., Wubbenhorst, B., D'Andrea, K., Pauken, K. E., Herati, R. S., Staupe, R. P., Schenkel, J. M., McGettigan, S., Kothari, S., George, S. M., Vonderheide, R. H., Amaravadi, R. K., Karakousis, G. C., Schuchter, L. M., Xu, X., Nathanson, K. L., Wolchok, J. D., Gangadhar, T. C. and Wherry, E. J.:T-cell invigoration to tumour burden ratio associated with anti-PD-1 response. Nature, 545:60-65, 2017.
PubMed

[11] 免疫細胞療法

P.67 掲載の参考文献
1) Rosenberg, S. A., Lotze, M. T., Yang, J. C., Topalian, S. L., Chang, A. E., Schwartzentruber, D. J., Aebersold, P., Leitman, S., Linehan, W. M., Seipp, C. A., White, D. E. and Steinberg, S. M.:Prospective randomized trial of high-dose interleukin-2 alone or in conjunction with lymphokine-activated killer cells for the treatment of patients with advanced cancer. J. Natl. Cancer Inst., 85:622-632, 1993.
 
2) Rosenberg, S. A., Yannelli, J. R., Yang, J. C., Topalian, S. L., Schwartzentruber, D. J., Weber, J. S., Parkinson, D. R., Seipp, C. A., Einhorn, J. H. and White, D. E.:Treatment of patients with metastatic melanoma with autologous tumor-infiltrating lymphocytes and interleukin 2. J. Natl. Cancer Inst., 86:1159-1166, 1994.
PubMed
3) Dranoff, G., Jaffee, E., Lazenby, A., Golumbek, P., Levitsky, H., Brose, K., Jackson, V., Hamada, H., Pardoll, D. and Mulligan, R. C.:Vaccination with irradiated tumor cells engineered to secrete murine granulocyte-macrophage colony-stimulating factor stimulates potent, specific, and long-lasting anti-tumor immunity. Proc. Natl. Acad. Sci. U. S. A., 90:3539-3543, 1993.
PubMed
4) Hulen, T. M., Chamberlain, C. A., Svane, I. M. and Met, O.:ACT up TIL now:The evolution of tumor-infiltrating lymphocytes in adoptive cell therapy for the treatment of solid tumors. Immuno., 1:194-211, 2021.
 
5) Chesney, J., Lewis, K. D., Kluger, H., Hamid, O., Whitman, E., Thomas, S., Wermke, M., Cusnir, M., Domingo-Musibay, E., Phan, G. Q., Kirkwood, J. M., Hassel, J. C., Orloff, M., Larkin, J., Weber, J., Furness, A. J. S., Khushalani, N. I., Medina, T., Egger, M. E., Graf Finckenstein, F., Jagasia, M., Hari, P., Sulur, G., Shi, W., Wu, X. and Sarnaik, A.:Efficacy and safety of lifileucel, a one-time autologous tumor-infiltrating lymphocyte (TIL) cell therapy, in patients with advanced melanoma after progression on immune checkpoint inhibitors and targeted therapies:Pooled analysis of consecutive cohorts of the C-144-01 study. J. Immunother. Cancer, 10:e005755, 2022.
 
6) Clay, T. M., Custer, M. C., Sachs, J., Hwu, P., Rosenberg, S. A. and Nishimura, M. I.:Efficient transfer of a tumor antigen-reactive TCR to human peripheral blood lymphocytes confers anti-tumor reactivity. J. Immunol., 163:507-513, 1999.
PubMed
7) Anderson, P., Aptsiauri, N., Ruiz-Cabello, F. and Garrido, F.:HLA class I loss in colorectal cancer:Implications for immune escape and immunotherapy. Cell. Mol. Immunol., 18:556-565, 2021.
 
8) Liu, Y., Yan, X., Zhang, F., Zhang, X., Tang, F., Han, Z. and Li, Y.:TCR-T immunotherapy:The challenges and solutions. Front. Oncol., 11:794183, 2022.
 
9) Morgan, R. A., Dudley, M. E., Wunderlich, J. R., Hughes, M. S., Yang, J. C., Sherry, R. M., Royal, R. E., Topalian, S. L., Kammula, U. S., Restifo, N. P., Zheng, Z., Nahvi, A., de Vries, C. R., Rogers-Freezer, L. J., Mavroukakis, S. A. and Rosenberg, S. A.:Cancer regression in patients after transfer of genetically engineered lymphocytes. Science, 314:126-129, 2006.
PubMed
10) Kunii, N., Horiguchi, S., Motohashi, S., Yamamoto, H., Ueno, N., Yamamoto, S., Sakurai, D., Taniguchi, M., Nakayama, T. and Okamoto, Y.:Combination therapy of in vitro-expanded natural killer T cells and alpha-galactosylceramide-pulsed antigen-presenting cells in patients with recurrent head and neck carcinoma. Cancer Sci,, 100:1092-1098, 2009.
PubMed
11) Parekh, V. V., Lalani, S., Kim, S., Halder, R., Azuma, M., Yagita, H., Kumar, V., Wu, L. and Kaer, L. V.:PD-1/PD-L blockade prevents anergy induction and enhances the anti-tumor activities of glycolipid-activated invariant NKT cells. J. Immunol., 182:2816-2826, 2009.
PubMed
12) Kamata, T., Suzuki, A., Mise, N., Ihara, F., Takami, M., Makita, Y., Horinaka, A., Harada, K., Kunii, N., Yoshida, S., Yoshino, I., Nakayama, T. and Motohashi, S.:Blockade of programmed death-1/programmed death ligand pathway enhances the antitumor immunity of human invariant natural killer T cells. Cancer Immunol. Immunother., 65:1477-1489, 2016.
PubMed
13) Ishii, K., Shimizu, M., Kogo, H., Negishi, Y., Tamura, H., Morita, R. and Takahashi, H.:A combination of check-point blockade and α-galactosylceramide elicits long-lasting suppressive effects on murine hepatoma cell growth in vivo. Immunobiology, 225:151860, 2020.
 
14) Wang, Y., Bhave, M. S., Yagita, H. and Cardell, S. L.:Natural killer T-cell agonist α-galactosylceramide and PD-1 blockade synergize to reduce tumor development in a preclinical model of colon cancer. Front. Immunol., 11:581301, 2020.
 

[12] ネオアンチゲンを用いたがん治療

P.72 掲載の参考文献
1) Topalian, S. L., Hodi, F. S., Brahmer, J. R., Gettinger, S. N., Smith, D. C., McDermott, D. F., Powderly, J. D., Carvajal, R. D., Sosman, J. A., Atkins, M. B., Leming, P. D., Spigel, D. R., Antonia, S. J., Horn, L., Drake, C. G., Pardoll, D. M., Chen, L., Sharfman, W. H., Anders, R. A., Taube, J. M., McMiller, T. L., Xu, H., Korman, A. J., Jure-Kunkel, M., Agrawal, S., McDonald, D., Kollia, G. D., Gupta, A., Wigginton, J. M. and Sznol, M.:Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N. Engl. J. Med., 366:2443-2454, 2012.
PubMed
2) Brahmer, J. R., Tykodi, S. S., Chow, L. Q., Hwu, W. J., Topalian, S. L., Hwu, P., Drake, C. G., Camacho, L. H., Kauh, J., Odunsi, K., Pitot, H. C., Hamid, O., Bhatia, S., Martins, R., Eaton, K., Chen, S., Salay, T. M., Alaparthy, S., Grosso, J. F., Korman, A. J., Parker, S. M., Agrawal, S., Goldberg, S. M., Pardoll, D. M., Gupta, A. and Wigginton, J. M.:Safety and activity of anti-PD-L1 antibody in patients with advanced cancer. N. Engl. J. Med., 366:2455-2465, 2012.
PubMed
3) Hazama, S., Tamada, K., Yamaguchi, Y., Kawakami, Y. and Nagano, H.:Current status of immunotherapy against gastrointestinal cancers and its biomarkers:Perspective for precision immunotherapy. Ann. Gastroenterol. Surg., 2:289-303, 2018.
PubMed
4) Boon, T. and van der Bruggen, P.:Human tumor antigens recognized by T lymphocytes. J. Exp. Med., 183:725-729, 1996.
 
5) Rosenberg, S. A., Yang, J. C. and Restifo, N. P.:Cancer immunotherapy:Moving beyond current vaccines. Nat. Med., 10:909-915, 2004.
PubMed
6) Nagorsen, D. and Thiel, E.:Clinical and immunologic responses to active specific cancer vaccines in human colorectal cancer. Clin. Cancer Res., 12:3064-3069, 2006.
PubMed
7) Le, D. T., Uram, J. N., Wang, H., Bartlett, B. R., Kemberling, H., Eyring, A. D., Skora, A. D., Luber, B. S., Azad, N. S., Laheru, D., Biedrzycki, B., Donehower, R. C., Zaheer, A., Fisher, G. A., Crocenzi, T. S., Lee, J. J., Duffy, S. M., Goldberg, R. M., de la Chapelle, A., Koshiji, M., Bhaijee, F., Huebner, T., Hruban, R. H., Wood, L. D., Cuka, N., Pardoll, D. M., Papadopoulos, N., Kinzler, K. W., Zhou, S., Cornish, T. C., Taube, J. M., Anders, R. A., Eshleman, J. R., Vogelstein, B. and Diaz, L. A. Jr.:PD-1 blockade in tumors with mismatch-repair deficiency. N. Engl. J. Med., 372:2509-2520, 2015.
 
8) Schumacher, T. N. and Schreiber, R. D.:Neoantigens in cancer immunotherapy. Science, 348:69-74, 2015.
PubMed
9) Zhao, X., Pan, X., Wang, Y. and Zhang, Y.:Targeting neoantigens for cancer immunotherapy. Biomark. Res., 9:61, 2021.
 
10) Hu, Z., Leet, D. E., Allesoe, R. L., Oliveira, G., Li, S., Luoma, A. M., Liu, J., Forman, J., Huang, T., Iorgulescu, J. B., Holden, R., Sarkizova, S., Gohil, S. H., Redd, R. A., Sun, J., Elagina, L., Giobbie-Hurder, A., Zhang, W., Peter, L., Ciantra, Z., Rodig, S., Olive, O., Shetty, K., Pyrdol, J., Uduman, M., Lee, P. C., Bachireddy, P., Buchbinder, E. I., Yoon, C. H., Neuberg, D., Pentelute, B. L., Hacohen, N., Livak, K. J., Shukla, S. A., Olsen, L. R., Barouch, D. H., Wucherpfennig, K. W., Fritsch, E. F., Keskin, D. B., Wu, C. J. and Ott, P. A.:Personal neoantigen vaccines induce persistent memory T cell responses and epitope spreading in patients with melanoma. Nat. Med., 27:515-525, 2021.
 
11) Postow, M. A., Callahan, M. K., Barker, C. A., Yamada, Y., Yuan, J., Kitano, S., Mu, Z., Rasalan, T., Adamow, M., Ritter, E., Sedrak, C., Jungbluth, A. A., Chua, R., Yang, A. S., Roman, R. A., Rosner, S., Benson, B., Allison, J. P., Lesokhin, A. M., Gnjatic, S. and Wolchok, J. D.:Immunologic correlates of the abscopal effect in a patient with melanoma. N. Engl. J. Med., 366:925-931, 2012.
 
12) Ott, P. A., Hu, Z., Keskin, D. B., Shukla, S. A., Sun, J., Bozym, D. J., Zhang, W., Luoma, A., Giobbie-Hurder, A., Peter, L., Chen, C., Olive, O., Carter, T. A., Li, S., Lieb, D. J., Eisenhaure, T., Gjini, E., Stevens, J., Lane, W. J., Javeri, I., Nellaiappan, K., Salazar, A. M., Daley, H., Seaman, M., Buchbinder, E. I., Yoon, C. H., Harden, M., Lennon, N., Gabriel, S., Rodig, S. J., Barouch, D. H., Aster, J. C., Getz, G., Wucherpfennig, K., Neuberg, D., Ritz, J., Lander, E. S., Fritsch, E. F., Hacohen, N. and Wu, C. J.:An immunogenic personal neoantigen vaccine for patients with melanoma. Nature, 547:217-221, 2017.
 
13) Keskin, D. B., Anandappa, A. J., Sun, J., Tirosh, I., Mathewson, N. D., Li, S., Oliveira, G., Giobbie-Hurder, A., Felt, K., Gjini, E., Shukla, S. A., Hu, Z., Li, L., Le, P. M., Allesoe, R. L., Richman, A. R., Kowalczyk, M. S., Abdelrahman, S., Geduldig, J. E., Charbonneau, S., Pelton, K., Iorgulescu, J. B., Elagina, L., Zhang, W., Olive, O., McCluskey, C., Olsen, L. R., Stevens, J., Lane, W. J., Salazar, A. M., Daley, H., Wen, P. Y., Chiocca, E. A., Harden, M., Lennon, N. J., Gabriel, S., Getz, G., Lander, E. S., Regev, A., Ritz, J., Neuberg, D., Rodig, S. J., Ligon, K. L., Suva, M. L., Wucherpfennig, K. W., Hacohen, N., Fritsch, E. F., Livak, K. J., Ott, P. A., Wu, C. J. and Reardon, D. A.:Neoantigen vaccine generates intratumoral T cell responses in phase Ib glioblastoma trial. Nature, 565:234-239, 2019.
 
14) Giannakis, M., Mu, X. J., Shukla, S. A., Qian, Z. R., Cohen, O., Nishihara, R., Bahl, S., Cao, Y., Amin-Mansour, A., Yamauchi, M., Sukawa, Y., Stewart, C., Rosenberg, M., Mima, K., Inamura, K., Nosho, K., Nowak, J. A., Lawrence, M. S., Giovannucci, E. L., Chan, A. T., Ng, K., Meyerhardt, J. A., Van Allen, E. M., Getz, G., Gabriel, S. B., Lander, E. S., Wu, C. J., Fuchs, C. S., Ogino, S. and Garraway, L. A.:Genomic correlates of immune-cell infiltrates in colorectal carcinoma. Cell Rep., 15:857-865, 2016.
PubMed
15) Tran, E., Robbins, P. F., Lu, Y. C., Prickett, T. D., Gartner, J. J., Jia, L., Pasetto, A., Zheng, Z., Ray, S., Groh, E. M., Kriley, I. R. and Rosenberg, S. A.:T-cell transfer therapy targeting mutant KRAS in cancer. N. Engl. J. Med., 375:2255-2262, 2016.
PubMed
16) Rosenberg, S. A. and Restifo, N. P.:Adoptive cell transfer as personalized immunotherapy for human cancer. Science, 348:62-68, 2015.
PubMed
17) Leidner, R., Sanjuan Silva, N., Huang, H., Sprott, D., Zheng, C., Shih, Y. P., Leung, A., Payne, R., Sutcliffe, K., Cramer, J., Rosenberg, S. A., Fox, B. A., Urba, W. J. and Tran, E.:Neoantigen T-cell receptor gene therapy in pancreatic cancer. N. Engl. J. Med., 386:2112-2119, 2022.
PubMed
18) Laumont, C. M., Vincent, K., Hesnard, L., Audemard, E., Bonneil, E., Laverdure, J. P., Gendron, P., Courcelles, M., Hardy, M. P., Cote, C., Durette, C., St-Pierre, C., Benhammadi, M., Lanoix, J., Vobecky, S., Haddad, E., Lemieux, S., Thibault, P. and Perreault, C.:Noncoding regions are the main source of targetable tumor-specific antigens. Sci. Transl. Med., 10:eaau5516, 2018.
PubMed
19) Kano, Y., Iguchi, T., Matsui, H., Adachi, K., Sakoda, Y., Miyakawa, T., Doi, S., Hazama, S., Nagano, H., Ueyama, Y. and Tamada, K.:Combined adjuvants of poly (I:C) plus LAG-3-Ig improve antitumor effects of tumor-specific T cells, preventing their exhaustion. Cancer Sci., 107:398-406, 2016.
PubMed
20) Matsui, H., Hazama, S., Tamada, K., Udaka, K., Irie, A., Nishimura, Y., Miyakawa, T., Doi, S., Nakajima, M., Kanekiyo, S., Tokumitsu, Y., Shindo, Y., Tomochika, S., Yoshida, S., Iida, M., Suzuki, N., Takeda, S., Yamamoto, S., Yoshino, S., Ueno, T. and Nagano, H.:Identification of a promiscuous epitope peptide derived from HSP70. J. Immunother., 42:244-250, 2019.
 
21) Nakajima, M., Hazama, S., Tamada, K., Udaka, K., Kouki, Y., Uematsu, T., Arima, H., Saito, A., Doi, S., Matsui, H., Shindo, Y., Matsukuma, S., Kanekiyo, S., Tokumitsu, Y., Tomochika, S., Iida, M., Yoshida, S., Nakagami, Y., Suzuki, N., Takeda, S., Yamamoto, S., Yoshino, S., Ueno, T. and Nagano, H.:A phase I study of multi-HLA-binding peptides derived from heat shock protein 70/glypican-3 and a novel combination adjuvant of hLAG-3Ig and poly-ICLC for patients with metastatic gastrointestinal cancers:YNP01 trial. Cancer Immunol. Immunother., 69:1651-1662, 2020.
 

[13] 複合免疫療法

P.78 掲載の参考文献
1) Chen, D. S. and Mellman, I.:Elements of cancer immunity and the cancer-immune set point. Nature, 541:321-330, 2017.
PubMed
2) Zhang, J., Shi, Z., Xu, X., Yu, Z. and Mi, J.:The influence of microenvironment on tumor immunotherapy. FEBS J., 286:4160-4175, 2019.
 
3) Meric-Bernstam, F., Larkin, J., Tabernero, J. and Bonini, C.:Enhancing anti-tumour efficacy with immunotherapy combinations. Lancet, 397:1010-1022, 2021.
PubMed
4) Wang, Q., Ju, X., Wang, J., Fan, Y., Ren, M. and Zhang, H.:Immunogenic cell death in anticancer chemotherapy and its impact on clinical studies. Cancer Lett., 438:17-23, 2018.
 
5) Dimeloe, S., Frick, C., Fischer, M., Gubser, P. M., Razik, L., Bantug, G. R., Ravon, M., Langenkamp, A. and Hess, C.:Human regulatory T cells lack the cyclophosphamide-extruding transporter ABCB1 and are more susceptible to cyclophosphamide-induced apoptosis. Eur. J. Immunol., 44:3614-3620, 2014.
PubMed
6) Gandhi, L., Rodriguez-Abreu, D., Gadgeel, S., Esteban, E., Felip, E., De Angelis, F., Domine, M., Clingan, P., Hochmair, M. J., Powell, S. F., Cheng, S. Y., Bischoff, H. G., Peled, N., Grossi, F., Jennens, R. R., Reck, M., Hui, R., Garon, E. B., Boyer, M., Rubio-Viqueira, B., Novello, S., Kurata, T., Gray, J. E., Vida, J., Wei, Z., Yang, J., Raftopoulos, H., Pietanza, M. C. and Garassino, M. C.;KEYNOTE-189 Investigators:Pembrolizumab plus chemotherapy in metastatic non-small-cell lung cancer. N. Engl. J. Med., 378:2078-2092, 2018.
PubMed
7) Paz-Ares, L., Ciuleanu, T. E., Cobo, M., Schenker, M., Zurawski, B., Menezes, J., Richardet, E., Bennouna, J., Felip, E., Juan-Vidal, O., Alexandru, A., Sakai, H., Lingua, A., Salman, P., Souquet, P. J., De Marchi, P., Martin, C., Perol, M., Scherpereel, A., Lu, S., John, T., Carbone, D. P., Meadows-Shropshire, S., Agrawal, S., Oukessou, A., Yan, J. and Reck, M.:First-line nivolumab plus ipilimumab combined with two cycles of chemotherapy in patients with non-small-cell lung cancer (CheckMate 9LA):An international, randomised, open-label, phase 3 trial. Lancet Oncol., 22:198-211, 2021.
PubMed
8) Schmid, P., Rugo, H. S., Adams, S., Schneeweiss, A., Barrios, C. H., Iwata, H., Dieras, V., Henschel, V., Molinero, L., Chui, S. Y., Maiya, V., Husain, A., Winer, E. P., Loi, S. and Emens, L. A.;IMpassion130 Investigators:Atezolizumab plus nab-paclitaxel as first-line treatment for unresectable, locally advanced or metastatic triple-negative breast cancer (IMpassion130):Updated efficacy results from a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Oncol., 21:44-59, 2020.
PubMed
9) Horn, L., Mansfield, A. S., Szczesna, A., Havel, L., Krzakowski, M., Hochmair, M. J., Huemer, F., Losonczy, G., Johnson, M. L., Nishio, M., Reck, M., Mok, T., Lam, S., Shames, D. S., Liu, J., Ding, B., Lopez-Chavez, A., Kabbinavar, F., Lin, W., Sandler, A. and Liu, S. V.;IMpower133 Study Group:First-line atezolizumab plus chemotherapy in extensive-stage small-cell lung cancer. N. Engl. J. Med., 379:2220-2229, 2018.
 
10) Kang, Y. K., Chen, L. T., Ryu, M. H., Oh, D. Y., Oh, S. C., Chung, H. C., Lee, K. W., Omori, T., Shitara, K., Sakuramoto, S., Chung, I. J., Yamaguchi, K., Kato, K., Sym, S. J., Kadowaki, S., Tsuji, K., Chen, J. S., Bai., L. Y., Oh, S. Y., Choda, Y., Yasui, H., Takeuchi, K., Hirashima, Y., Hagihara, S. and Boku, N.:Nivolumab plus chemotherapy versus placebo plus chemotherapy in patients with HER2-negative, untreated, unresectable advanced or recurrent gastric or gastro-oesophageal junction cancer (ATTRACTION-4):A randomised, multicentre, double-blind, placebo-controlled, phase 3 trial. Lancet Oncol., 23:234-247, 2022.
 
11) Sun, J. M., Shen, L., Shah, M. A., Enzinger, P., Adenis, A., Doi, T., Kojima, T., Metges, J. P., Li, Z., Kim, S. B., Cho, B. C., Mansoor, W., Li, S. H., Sunpaweravong, P., Maqueda, M. A., Goekkurt, E., Hara, H., Antunes, L., Fountzilas, C., Tsuji, A., Oliden, V. C., Liu, Q., Shah, S., Bhagia, P. and Kato, K.;KEYNOTE-590 Investigators:Pembrolizumab plus chemotherapy versus chemotherapy alone for first-line treatment of advanced oesophageal cancer (KEYNOTE-590):A randomised, placebo-controlled, phase 3 study. Lancet, 398:759-771, 2021.
PubMed
12) Burtness, B., Harrington, K. J., Greil, R., Soulieres, D., Tahara, M., de Castro, G. Jr., Psyrri, A., Baste, N., Neupane, P., Bratland, A., Fuereder, T., Hughes, B. G. M., Mesia, R., Ngamphaiboon, N., Rordorf, T., Wan Ishak, W. Z., Hong, R. L., Gonzalez Mendoza, R., Roy, A., Zhang, Y., Gumuscu, B., Cheng, J. D., Jin, F. and Rischin, D.;KEYNOTE-048 Investigators:Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048):A randomised, open-label, phase 3 study. Lancet, 394:1915-1928, 2019.
 
13) Jotte, R., Cappuzzo, F., Vynnychenko, I., Stroyakovskiy, D., Rodriguez-Abreu, D., Hussein, M., Soo, R., Conter, H. J., Kozuki, T., Huang, K. C., Graupner, V., Sun, S. W., Hoang, T., Jessop, H., McCleland, M., Ballinger, M., Sandler, A. and Socinski, M. A.:Atezolizumab in combination with carboplatin and nab-paclitaxel in advanced squamous NSCLC (IMpower131):Results from a randomized phase III trial. J. Thorac. Oncol., 15:1351-1360, 2020.
PubMed
14) Corso, C. D., Ali, A. N. and Diaz, R.:Radiation-induced tumor neoantigens:Imaging and therapeutic implications. Am. J. Cancer Res., 1:390-412, 2011.
 
15) Shi, F., Wang, X., Teng, F., Kong, L. and Yu, J.:Abscopal effect of metastatic pancreatic cancer after local radiotherapy and granulocyte-macrophage colony-stimulating factor therapy. Cancer Biol. Ther., 18:137-141, 2017.
 
16) Brahmer, J. R., Tykodi, S. S., Chow, L. Q., Hwu, W. J., Topalian, S. L., Hwu, P., Drake, C. G., Camacho, L. H., Kauh, J., Odunsi, K., Pitot, H. C., Hamid, O., Bhatia, S., Martins, R., Eaton, K., Chen, S., Salay, T. M., Alaparthy, S., Grosso, J. F., Korman, A. J., Parker, S. M., Agrawal, S., Goldberg, S. M., Pardoll, D. M., Gupta, A. and Wigginton, J. M.:Safety and activity of anti-PD-L1 antibody in patients with advanced cancer. N. Engl. J. Med., 366:2455-2465, 2012.
PubMed
17) Shaverdian, N., Lisberg, A. E., Bornazyan, K., Veruttipong, D., Goldman, J. W., Formenti, S. C., Garon, E. B. and Lee, P.:Previous radiotherapy and the clinical activity and toxicity of pembrolizumab in the treatment of non-small-cell lung cancer:A secondary analysis of the KEYNOTE-001 phase 1 trial. Lancet Oncol., 18:895-903, 2017.
 
18) Antonia, S. J., Villegas, A., Daniel, D., Vicente, D., Murakami, S., Hui, R., Yokoi, T., Chiappori, A., Lee, K. H., de Wit, M., Cho, B. C., Bourhaba, M., Quantin, X., Tokito, T., Mekhail, T., Planchard, D., Kim, Y. C., Karapetis, C. S., Hiret, S., Ostoros, G., Kubota, K., Gray, J. E., Paz-Ares, L., de Castro Carpeno, J., Wadsworth, C., Melillo, G., Jiang, H., Huang, Y., Dennis, P. A. and Ozguroglu, M.;PACIFIC Investigators:Durvalumab after chemoradiotherapy in stage III non-small-cell lung cancer. N. Engl. J. Med., 377:1919-1929, 2017.
PubMed
19) Motzer, R. J., Robbins, P. B., Powles, T., Albiges, L., Haanen, J. B., Larkin, J., Mu, X. J., Ching, K. A., Uemura, M., Pal, S. K., Alekseev, B., Gravis, G., Campbell, M. T., Penkov, K., Lee, J. L., Hariharan, S., Wang, X., Zhang, W., Wang, J., Chudnovsky, A., di Pietro, A., Donahue, A. C. and Choueiri, T. K.:Avelumab plus axitinib versus sunitinib in advanced renal cell carcinoma:Biomarker analysis of the phase 3 JAVELIN Renal 101 trial. Nat. Med., 26:1733-1741, 2020.
PubMed
20) Ascierto, P. A., Ferrucci, P. F., Fisher, R., Del Vecchio, M., Atkinson, V., Schmidt, H., Schachter, J., Queirolo, P., Long, G. V., Di Giacomo, A. M., Svane, I. M., Lotem, M., Bar-Sela, G., Couture, F., Mookerjee, B., Ghori, R., Ibrahim, N., Moreno, B. H. and Ribas, A.:Dabrafenib, trametinib and pembrolizumab or placebo in BRAF-mutant melanoma. Nat. Med., 25:941-946, 2019.
PubMed
21) Eng, C., Kim, T. W., Bendell, J., Argiles, G., Tebbutt, N. C., Di Bartolomeo, M., Falcone, A., Fakih, M., Kozloff, M., Segal, N. H., Sobrero, A., Yan, Y., Chang, I., Uyei, A., Roberts, L. and Ciardiello, F.;IMblaze370 Investigators:Atezolizumab with or without cobimetinib versus regorafenib in previously treated metastatic colorectal cancer (IMblaze370):A multicentre, open-label, phase 3, randomised, controlled trial. Lancet Oncol., 20:849-861, 2019.
PubMed
22) Larkin, J., Hodi, F. S. and Wolchok, J. D.:Combined nivolumab and ipilimumab or monotherapy in untreated melanoma. N. Engl. J. Med., 373:1270-1271, 2015.
 
23) Cho, B. C., Abreu, D. R., Hussein, M., Cobo, M., Patel, A. J., Secen, N., Lee, K. H., Massuti, B., Hiret, S., Yang, J. C. H., Barlesi, F., Lee, D. H., Ares, L. P., Hsieh, R. W., Patil, N. S., Twomey, P., Yang, X., Meng, R. and Johnson, M. L.:Tiragolumab plus atezolizumab versus placebo plus atezolizumab as a first-line treatment for PD-L1-selected non-small-cell lung cancer (CITYSCAPE):Primary and follow-up analyses of a randomised, double-blind, phase 2 study. Lancet Oncol., 23:781-792, 2022.
PubMed
24) Otano, I., Azpilikueta, A., Glez-Vaz, J., Alvarez, M., Medina-Echeverz, J., Cortes-Dominguez, I., Ortiz-de-Solorzano, C., Ellmark, P., Fritzell, S., Hernandez-Hoyos, G., Nelson, M. H., Ochoa, M. C., Bolanos, E., Cuculescu, D., Jauregui, P., Sanchez-Gregorio, S., Etxeberria, I., Rodriguez-Ruiz, M. E., Sanmamed, M. F., Teijeira, A., Berraondo, P. and Melero, I.:CD137 (4-1BB) costimulation of CD8+ T cells is more potent when provided in cis than in trans with respect to CD3-TCR stimulation. Nat. Commun., 12:7296, 2021.
 
25) Turaj, A. H., Cox, K. L., Penfold, C. A., French, R. R., Mockridge, C. I., Willoughby, J. E., Tutt, A. L., Griffiths, J., Johnson, P. W. M., Glennie, M. J., Levy, R., Cragg, M. S. and Lim, S. H.:Augmentation of CD134 (OX40)-dependent NK anti-tumour activity is dependent on antibody cross-linking. Sci. Rep., 8:2278, 2018.
 
26) Sanmamed, M. F., Perez-Gracia, J. L., Schalper, K. A., Fusco, J. P., Gonzalez, A., Rodriguez-Ruiz, M. E., Onate, C., Perez, G., Alfaro, C., Martin-Algarra, S., Andueza, M. P., Gurpide, A., Morgado, M., Wang, J., Bacchiocchi, A., Halaban, R., Kluger, H., Chen, L., Sznol, M. and Melero, I.:Changes in serum interleukin-8 (IL-8) levels reflect and predict response to anti-PD-1 treatment in melanoma and non-small-cell lung cancer patients. Ann. Oncol., 28:1988-1995, 2017.
 
27) Mace, T. A., Shakya, R., Pitarresi, J. R., Swanson, B., McQuinn, C. W., Loftus, S., Nordquist, E., Cruz-Monserrate, Z., Yu, L., Young, G., Zhong, X., Zimmers, T. A., Ostrowski, M. C., Ludwig, T., Bloomston, M., Bekaii-Saab, T. and Lesinski, G. B.:IL-6 and PD-L1 antibody blockade combination therapy reduces tumour progression in murine models of pancreatic cancer. Gut, 67:320-332, 2018.
PubMed
28) Kobold, S., Pantelyushin, S., Rataj, F. and Vom Berg, J.:Rationale for combining bispecific T cell activating antibodies with checkpoint blockade for cancer therapy. Front. Oncol., 8:285, 2018.
PubMed
29) Grenier, J. M., Yeung, S. T. and Khanna, K. M.:Combination immunotherapy:Taking cancer vaccines to the next level. Front. Immunol., 9:610, 2018.
 
30) Jackson, H. J., Rafiq, S. and Brentjens, R. J.:Driving CAR T-cells forward. Nat. Rev. Clin. Oncol., 13:370-383, 2016.
 
31) Brentjens, R. J., Riviere, I., Park, J. H., Davila, M. L., Wang, X., Stefanski, J., Taylor, C., Yeh, R., Bartido, S., Borquez-Ojeda, O., Olszewska, M., Bernal, Y., Pegram, H., Przybylowski, M., Hollyman, D., Usachenko, Y., Pirraglia, D., Hosey, J., Santos, E., Halton, E., Maslak, P., Scheinberg, D., Jurcic, J., Heaney, M., Heller, G., Frattini, M. and Sadelain, M.:Safety and persistence of adoptively transferred autologous CD19-targeted T cells in patients with relapsed or chemotherapy refractory B-cell leukemias. Blood, 118:4817-4828, 2011.
PubMed
32) Porter, D. L., Levine, B. L., Kalos, M., Bagg, A. and June, C. H.:Chimeric antigen receptor-modified T cells in chronic lymphoid leukemia. N. Engl. J. Med., 365:725-733, 2011.
PubMed
33) Chmielewski, M., Kopecky, C., Hombach, A. A. and Abken, H.:IL-12 release by engineered T cells expressing chimeric antigen receptors can effectively Muster an antigen-independent macrophage response on tumor cells that have shut down tumor antigen expression. Cancer Res., 71:5697-5706,
PubMed
34) Tschernia, N. P., Norberg, S. M. and Gulley, J. L.:CAR T cells reach clinical milestone in prostate cancer. Nat. Med., 28:635-636, 2022.
 
35) Luksik, A. S., Yazigi, E., Shah, P. and Jackson, C. M.:CAR T cell therapy in glioblastoma:Overcoming challenges related to antigen expression. Cancers, 15:1414, 2023.
PubMed
36) Chong, E. A., Melenhorst, J. J., Lacey, S. F., Ambrose, D. E., Gonzalez, V., Levine, B. L., June, C. H. and Schuster, S. J.:PD-1 blockade modulates chimeric antigen receptor (CAR)-modified T cells:Refueling the CAR. Blood, 129:1039-1041, 2017.
PubMed
37) Choucair, K., Morand, S., Stanbery, L., Edelman, G., Dworkin, L. and Nemunaitis, J.:TMB:A promising immune-response biomarker, and potential spearhead in advancing targeted therapy trials. Cancer Gene. Ther., 27:841-853, 2020.
PubMed
38) Patel, S. P. and Kurzrock, R.:PD-L1 expression as a predictive biomarker in cancer immunotherapy. Mol. Cancer Ther., 14:847-856, 2015.
PubMed
39) Nakaya, A., Kurata, T., Yoshioka, H., Takeyasu, Y., Niki, M., Kibata, K., Satsutani, N., Ogata, M., Miyara, T. and Nomura, S.:Neutrophil-to-lymphocyte ratio as an early marker of outcomes in patients with advanced non-small-cell lung cancer treated with nivolumab. Int. J. Clin. Oncol., 23:634-640, 2018.
PubMed
40) Harel, M., Ortenberg, R., Varanasi, S. K., Mangalhara, K. C., Mardamshina, M., Markovits, E., Baruch, E. N., Tripple, V., Arama-Chayoth, M., Greenberg, E., Shenoy, A., Ayasun, R., Knafo, N., Xu, S., Anafi, L., Yanovich-Arad, G., Barnabas, G. D., Ashkenazi, S., Besser, M. J., Schachter, J., Bosenberg, M., Shadel, G. S., Barshack, I., Kaech, S. M., Markel, G. and Geiger, T.:Proteomics of melanoma response to immunotherapy reveals mitochondrial dependence. Cell, 179:236-250, 2019.
PubMed
41) Blank, C. U., Haanen, J. B., Ribas, A. and Schumacher, T. N.:The "cancer immunogram". Science, 352:658-660, 2016.
PubMed

[14] 免疫抑制細胞をターゲットにしたがん治療

P.86 掲載の参考文献
1) Hori, S., Nomura, T. and Sakaguchi, S.:Control of regulatory T cell development by the transcription factor Foxp3. Science, 299:1057-1061, 2003.
 
2) Youn, J. I., Nagaraj, S., Collazo, M. and Gabrilovich, D. I.:Subsets of myeloid-derived suppressor cells in tumor-bearing mice. J. Immunol., 181:5791-5802, 2008.
PubMed
3) Zea, A. H., Rodriguez, P. C., Atkins, M. B., Hernandez, C., Signoretti, S., Zabaleta, J., McDermott, D., Quiceno, D., Youmans, A., O'Neill, A., Mier, J. and Ochoa, A. C.:Arginase-producing myeloid suppressor cells in renal cell carcinoma patients:A mechanism of tumor evasion. Cancer Res., 65:3044-3048, 2005.
PubMed
4) Kusmartsev, S., Su, Z., Heiser, A., Dannull, J., Eruslanov, E., Kubler, H., Yancey, D., Dahm, P. and Vieweg, J.:Reversal of myeloid cell-mediated immunosuppression in patients with metastatic renal cell carcinoma. Clin. Cancer Res., 14:8270-8278, 2008.
PubMed
5) Greten, T. F., Manns, M. P. and Korangy, F.:Myeloid derived suppressor cells in human diseases. Int. Immunopharmacol., 11:802-807, 2011.
PubMed
6) Mizoguchi, A. and Bhan, A. K.:A case for regulatory B cells. J. Immunol., 176:705-710, 2006.
PubMed
7) Yanaba, K., Bouaziz, J. D., Haas, K. M., Poe, J. C., Fujimoto, M. and Tedder, T. F.:A regulatory B cell subset with a unique CD1dhiCD5+ phenotype controls T cell-dependent inflammatory responses. Immunity, 28:639-650, 2008.
PubMed
8) Matsushita, T., Yanaba, K., Bouaziz, J. D., Fujimoto, M. and Tedder, T. F.:Regulatory B cells inhibit EAE initiation in mice while other B cells promote disease progression. J. Clin. Invest., 118:3420-3430, 2008.
PubMed
9) DiLillo, D. J., Matsushita, T. and Tedder, T. F.:B10 cells and regulatory B cells balance immune responses during inflammation, autoimmunity, and cancer. Ann. N. Y. Acad. Sci., 1183:38-57, 2010.
PubMed
10) Olkhanud, P. B., Damdinsuren, B., Bodogai, M., Gress, R. E., Sen, R., Wejksza, K., Malchinkhuu, E., Wersto, R. P. and Biragyn, A.:Tumor-evoked regulatory B cells promote breast cancer metastasis by converting resting CD4+ T cells to T-regulatory cells. Cancer Res., 71:3505-3515, 2011.
 
11) Chaput, N., Louafi, S., Bardier, A., Charlotte, F., Vaillant, J. C., Mngaux, F., Rosenzwajg, M., Lemoine, F., Klatzmann, D. and Taieb, J.:Identification of CD8+CD25+Foxp3+ suppressive T cells in colorectal cancer tissue. Gut, 58:520-529, 2009.
 
12) Groh, V., Smythe, K., Dai, Z. and Spies, T.:Fas-ligand-mediated paracrine T cell regulation by the receptor NKG2D in tumor immunity. Nat. Immunol., 7:755-762, 2006.
PubMed
13) Peng, G., Wang, H. Y., Peng, W., Kiniwa, Y., Seo, K. H. and Wang, R. F.:Tumor-infiltrating gammadelta T cells suppress T and dendritic cell function via mechanisms controlled by a unique toll-like receptor signaling pathway. Immunity, 27:334-348, 2007.
 
14) Choi, H. S., Ha, S. Y., Kim, H. M., Ahn, S. M., Kang, M. S., Kim, K. M., Choi, M. G., Lee, J. H., Sohn, T. S., Bae, J. M., Kim, S. and Kang, E. S.:The prognostic effects of tumor infiltrating regulatory T cells and myeloid derived suppressor cells assessed by multicolor flow cytometry in gastric cancer patients. Oncotarget, 7:7940-7951, 2016.
PubMed
15) Saito, T., Nishikawa, H., Wada, H., Nagano, Y., Sugiyama, D., Atarashi, K., Maeda, Y., Hamaguchi, M., Ohkura, N., Sato, E., Nagase, H., Nishimura, J., Yamamoto, H., Takiguchi, S., Tanoue, T., Suda, W., Morita, H., Hattori, M., Honda, K., Mori, M., Doki, Y. and Sakaguchi, S.:Two FOXP3+CD4+ T cell subpopulations distinctly control the prognosis of colorectal cancers. Nat. Med., 22:679-684, 2016.
PubMed
16) Zhou, X., Su, Y. X., Lao, X. M., Liang, Y. J. and Liao, G. Q.:CD19+IL-10+ regulatory B cells affect survival of tongue squamous cell carcinoma patients and induce resting CD4+ T cells to CD4+Foxp3+ regulatory T cells. Oral Oncol., 53:27-35, 2016.
PubMed
17) Murakami, Y., Saito, H., Shimizu, S., Kono, Y., Shishido, Y., Miyatani, K., Matsunaga, T., Fukumoto, Y., Ashida, K., Sakabe, T., Nakayama, Y. and Fujiwara, Y.:Increased regulatory B cells are involved in immune evasion in patients with gastric cancer. Sci. Rep., 9:13083, 2019.
PubMed
18) Hodi, F. S., O'Day, S. J., McDermott, D. F., Weber, R. W., Sosman, J. A., Haanen, J. B., Gonzalez, R., Robert, C., Schadendorf, D., Hassel, J. C., Akerley, W., van den Eertwegh, A. J., Lutzky, J., Lorigan, P., Vaubel, J. M., Linette, G. P., Hogg, D., Ottensmeier, C. H., Lebb, C., Peschel, C., Quirt, I., Clark, J. I., Wolchok, J. D., Weber, J. S., Tian, J., Yellin, M. J., Nichol, G. M., Hoos, A. and Urba, W. J.:Improved survival with ipilimumab in patients with metastatic melanoma. N. Engl. J. Med., 363:711-723, 2010.
 
19) Kurose, K., Ohue, Y., Wada, H., Iida, S., Ishida, T., Kojima, T., Doi, T., Suzuki, S., Isobe, M., Funakoshi, T., Kakimi, K., Nishikawa, H., Udono, H., Oka, M., Ueda, R. and Nakayama, E.:Phase Ia study of Foxp3+ CD4 Treg depletion by infusion of a humanized anti-CCR4 antibody, KW-0761, in cancer patients. Clin. Cancer Res., 21:4327-4336, 2015.
PubMed
20) Maeda, Y., Wada, H., Sugiyama, D., Saito, T., Irie, T., Itahashi, K., Minoura, K., Suzuki, S., Kojima, T., Kakimi, K., Nakajima, J., Funakoshi, T., Iida, S., Oka, M., Shimamura, T., Doi, T., Doki, Y., Nakayama, E., Ueda, R. and Nishikawa, H.:Depletion of central memory CD8+ T cells might impede the antitumor therapeutic effect of mogamulizumab. Nat. Commun., 12:7280, 2021.
PubMed
21) Hayatsu, N., Miyao, T., Tachibana, M., Murakami, R., Kimura, A., Kato, T., Kawakami, E., Endo, T. A., Setoguchi, R., Watarai, H., Nishikawa, T., Yasuda, T., Yoshida, H. and Hori, S.:Analyses of a mutant Foxp3 allele reveal BATF as a critical transcription factor in the differentiation and accumulation of tissue regulatory T cells. Immunity, 47:268-283, 2017.
PubMed
22) Itahashi, K., Irie, T., Yuda, J., Kumagai, S., Tanegashima, T., Lin, Y. T., Watanabe, S., Goto, Y., Suzuki, J., Aokage, K., Tsuboi, M., Minami, Y., Ishii, G., Ohe, Y., Ise, W., Kurosaki, T., Suzuki, Y., Koyama, S. and Nishikawa, H.:BATF epigenetically and transcriptionally controls the activation program of regulatory T cells in human tumors. Sci. Immunol., 7:eabk0957, 2022.
PubMed
23) Mirza, N., Fishman, M., Fricke, I., Dunn, M., Neuger, A. M., Frost, T. J., Lush, R. M., Antonia, S. and Gabrilovich, D. I.:All-trans-retinoic acid improves differentiation of myeloid cells and immune response in cancer patients. Cancer Res., 66:9299-9307, 2006.
PubMed
24) Nefedova, Y., Fishman, M., Sherman, S., Wang, X., Beg, A. A. and Gabrilovich, D. I.:Mechanism of all-trans retinoic acid effect on tumor-associated myeloid-derived suppressor cells. Cancer Res., 67:11021-11028, 2007.
PubMed
25) Lathers, D. M., Clark, J. I., Achille, N. J. and Young, M. R.:Phase 1B study to improve immune responses in head and neck cancer patients using escalating doses of 25-hydroxyvitamin D3. Cancer Immunol. Immunother., 53:422-430, 2004.
 
26) Kodumudi, K. N., Woan, K., Gilvary, D. L., Sahakian, E., Wei, S. and Djeu, J. Y.:A novel chemoimmunomodulating property of docetaxel:Suppression of myeloid-derived suppressor cells in tumor bearers. Clin. Cancer Res., 16:4583-4594, 2010.
PubMed
27) Vincent, J., Mignot, G., Chalmin, F., Ladoire, S., Bruchard, M., Chevriaux, A., Martin, F., Apetoh, L., Rebe, C. and Ghiringhelli, F.:5-fluorouracil selectively kills tumor-associated myeloid-derived suppressor cells resulting in enhanced T cell-dependent antitumor immunity. Cancer Res., 70:3052-3061, 2010.
PubMed
28) Suzuki, E., Kapoor, V., Jassar, A. S., Kaiser, L. R. and Albelda, S. M.:Gemcitabine selectively eliminates splenic Gr-1+/CD11b+ myeloid suppressor cells in tumor-bearing animals and enhances antitumor immune activity. Clin. Cancer Res., 11:6713-6721, 2005.
PubMed
29) Ko, J. S., Zea, A. H., Rini, B. I., Ireland, J. L., Elson, P., Cohen, P., Golshayan, A., Rayman, P. A., Wood, L., Garcia, J., Dreicer, R., Bukowski, R. and Finke, J. H.:Sunitinib mediates reversal of myeloid-derived suppressor cell accumulation in renal cell carcinoma patients. Clin. Cancer Res., 15:2148-2157, 2009.
PubMed
30) Rodriguez, P. C., Hernandez, C. P., Quiceno, D., Dubinett, S. M., Zabaleta, J., Ochoa, J. B., Gilbert, J. and Ochoa, A. C.:Arginase I in myeloid suppressor cells is induced by COX-2 in lung carcinoma. J. Exp. Med., 202:931-939, 2005.
PubMed
31) Melani, C., Sangaletti, S., Barazzetta, F. M., Werb, Z. and Colombo, M. P.:Amino-biphosphonate-mediated MMP-9 inhibition breaks the tumor-bone marrow axis responsible for myeloid-derived suppressor cell expansion and macrophage infiltration in tumor stroma. Cancer Res., 67:11438-11446, 2007.
PubMed
32) Dudley, M. E., Wunderlich, J. R., Yang, J. C., Sherry, R. M., Topalian, S. L., Restifo, N. P., Royal, R. E., Kammula, U., White, D. E., Mavroukakis, S. A., Rogers, L. J., Gracia, G. J., Jones, S. A., Mangiameli, D. P., Pelletier, M. M., Gea-Banacloche, J., Robinson, M. R., Berman, D. M., Filie, A. C., Abati, A. and Rosenberg, S. A.:Adoptive cell transfer therapy following non-myeloablative but lymphodepleting chemotherapy for the treatment of patients with refractory metastatic melanoma. J. Clin. Oncol., 23:2346-2357, 2005.
PubMed

[15] 抗がん剤・分子標的薬との複合免疫療法

P.94 掲載の参考文献
1) Taniura, T., Iida, Y., Kotani, H., Ishitobi, K., Tajima, Y. and Harada, M.:Immunogenic chemotherapy in two mouse colon cancer models. Cancer Sci., 111:3527-3539, 2020.
PubMed
2) 原田守:免疫制御剤(1)抗がん免疫応答修飾剤としての化学療法剤. 実験医学, 34:1960-1966, 2016.
Medical*Online
3) Kroemer, G., Galluzzi, L., Kepp, O. and Zitvogel, L.:Immunogenic cell death in cancer therapy. Annu. Rev. Immunol., 31:51-72, 2013.
PubMed
4) Khoo, L. T. and Chen, L. Y.:Role of the cGAS-STING pathway in cancer development and oncotherapeutic approaches. EMBO Rep., 19:e46935, 2018.
 
5) Bruchard, M., Mignot, G., Derangre, V., Chalmin, F., Chevriaux, A., Vgran, F., Boireau, W., Simon, B., Ryffel, B., Connat, J. L., Kanellopoulos, J., Martin, F., Rebe, C., Apetoh, L. and Ghiringhelli, F.:Chemotherapy-triggered cathepsin B release in myeloid-derived suppressor cells activates the Nlrp3 inflammasome and promotes tumor growth. Nat. Med., 19:57-64, 2013.
 
6) Ruffell, B., Chang-Strachan, D., Chan, V., Rosenbusch, A., Ho, C. M., Pryer, N., Daniel, D., Hwang, E. S., Rugo, H. S. and Coussens, L. M.:Macrophage IL-10 blocks CD8+ T cell-dependent responses to chemotherapy by suppressing IL-12 expression in intratumoral dendritic cells. Cancer Cell, 26:623-637, 2014.
PubMed
7) Ding, Z. C., Munn, D. H. and Zhou, G.:Chemotherapy-induced myeloid suppressor cells and antitumor immunity:The Janus face of chemotherapy in immunomodulation. Oncoimmunology, 3:e954471, 2014.
 
8) Takeuchi, S., Baghdadi, M., Tsuchikawa, T., Wada, H., Nakamura, T., Abe, H., Nakanishi, S., Usui, Y., Higuchi, K., Takahashi, M., Inoko, K., Sato, S., Takano, H., Shichinohe, T., Seino, K. and Hirano, S.:Chemotherapy-derived inflammatory responses accelerate the formation of immunosuppressive myeloid cells in the tissue microenvironment of human pancreatic cancer. Cancer Res., 75:2629-2640, 2015.
PubMed
9) Peng, J., Hamanishi, J., Matsumura, N., Abiko, K., Murat, K., Baba, T., Yamaguchi, K., Horikawa, N., Hosoe, Y., Murphy, S. K., Konishi, I. and Mandai, M.:Chemotherapy induces programmed cell death-ligand 1 overexpression via the Nuclear Factor-κB to foster an immunosuppressive tumor microenvironment in ovarian cancer. Cancer Res., 75:5034-5045, 2015.
 
10) Saleh, T., Tyutyunyk-Massey, L. and Gewirtz, D. A.:Tumor cell escape from therapy-induced senescence as a model of disease recurrence after dormancy. Cancer Res., 79:1044-1046, 2019.
 
11) Simova, J., Sapega, O., Imrichova, T., Stepanek, I., Kyjacova, L., Mikyskova, R., Indrova, M., Bieblova, J., Bubenik, J., Bartek, J., Hodny, Z. and Reinis, M.:Tumor growth accelerated by chemotherapy-induced senescent cells is suppressed by treatment with IL-12 producing cellular vaccines. Oncotarget, 7:54952-54964, 2016.
PubMed
12) Watanabe, S., Kawamoto, S., Ohtani, N. and Hara, E.:Impact of senescence-associated secretory phenotype and its potential as a therapeutic target for senescence-associated diseases. Cancer Sci., 108:563-569, 2017.
PubMed
13) Inao, T., Kotani, H., Iida, Y., Kartika, I. D., Okimoto, T., Tanino, R., Shiba, E. and Harada, M.:Different sensitivities of senescent breast cancer cells to immune cell-mediated cytotoxicity. Cancer Sci., 110:2690-2699, 2019.
PubMed
14) Okimoto, T., Kotani, H., Iida, Y., Koyanagi, A., Tanino, R., Tsubata, Y., Isobe, T. and Harada, M.:Pemetrexed sensitizes human lung cancer cells to cytotoxic immune cells. Cancer Sci., 111:1910-1920, 2020.
PubMed
15) Teh, J. L. F. and Aplin, A. E.:Arrested developments:CDK4/6 inhibitor resistance and alterations in the tumor immune microenvironment. Clin. Cancer Res., 25:921-927, 2019.
PubMed
16) Patnaik, A., Rosen, L. S., Tolaney, S. M., Tolcher, A. W., Goldman, J. W., Gandhi, L., Papadopoulos, K. P., Beeram, M., Rasco, D. W., Hilton, J. F., Nasir, A., Beckmann, R. P., Schade, A. E., Fulford, A. D., Nguyen, T. S., Martinez, R., Kulanthaivel, P., Li, L. Q., Frenzel, M., Cronier, D. M., Chan, E. M., Flaherty, K. T., Wen, P. Y. and Shapiro, G. I.:Efficacy and safety of abemaciclib, an inhibitor of CDK4 and CDK6, for patients with breast cancer, non-small cell lung cancer, and other solid tumors. Cancer Discov., 6:740-753, 2016.
PubMed
17) Goel, S., DeCristo, M. J., Watt, A. C., BrinJones, H., Sceneay, J., Li, B. B., Khan, N., Ubellacker, J. M., Xie, S., Metzger-Filho, O., Hoog, J., Ellis, M. J., Ma, C. X., Ramm, S., Krop, I. E., Winer, E. P., Roberts, T. M., Kim, H. J., McAllister, S. S. and Zhao, J. J.:CDK4/6 inhibition triggers anti-tumour immunity. Nature, 548:471-475, 2017.
 
18) Deng, J., Wang, E. S., Jenkins, R. W., Li, S., Dries, R., Yates, K., Chhabra, S., Huang, W., Liu, H., Aref, A. R., Ivanova, E., Paweletz, C. P., Bowden, M., Zhou, C. W., Herter-Sprie, G. S., Sorrentino, J. A., Bisi, J. E., Lizotte, P. H., Merlino, A. A., Quinn, M. M., Bufe, L. E., Yang, A., Zhang, Y., Zhang, H., Gao, P., Chen, T., Cavanaugh, M. E., Rode, A. J., Haines, E., Roberts, P. J., Strum, J. C., Richards, W. G., Lorch, J. H., Parangi, S., Gunda, V., Boland, G. M., Bueno, R., Palakurthi, S., Freeman, G. J., Ritz, J., Haining, W. N., Sharpless, N. E., Arthanari, H., Shapiro, G. I., Barbie, D. A., Gray, N. S. and Wong, K. K.:CDK4/6 inhibition augments antitumor immunity by enhancing T-cell activation. Cancer Discov., 8:216-233, 2018.
 
19) Schaer, D. A., Beckmann, R. P., Dempsey, J. A., Huber, L., Forest, A., Amaladas, N., Li, Y., Wang, Y. C., Rasmussen, E. R., Chin, D., Capen, A., Carpenito, C., Staschke, K. A., Chung, L. A., Litchfield, L. M., Merzoug, F. F., Gong, X., Iversen, P. W., Buchanan, S., de Dios, A., Novosiadly, R. D. and Kalos, M.:The CDK4/6 inhibitor abemaciclib induces a T cell inflamed tumor microenvironment and enhances the efficacy of PD-L1 checkpoint blockade. Cell Rep., 22:2978-2994, 2018.
 

[16] がん免疫サイクルと免疫編集

P.101 掲載の参考文献
1) Coley, W. B.:II. Contribution to the knowledge of sarcoma. Ann. Surg., 14:199-220, 1891.
 
2) Burnet, F. M.:Implications of immunological surveillance for cancer therapy. Isr. J. Med. Sci., 7:9-16, 1971.
PubMed
3) Thomas, L.:On immunosurveillance in human cancer. Yale J. Biol. Med., 55:329-333, 1982.
PubMed
4) Dunn, G. P., Bruce, A. T., Ikeda, H., Old, L. J. and Schreiber, R. D.:Cancer immunoediting:From immunosurveillance to tumor escape. Nat. Immunol., 3:991-998, 2002.
PubMed
5) Schreiber, R. D., Old, L. J. and Smyth, M. J.:Cancer immunoediting:Integrating immunity's roles in cancer suppression and promotion. Science, 331:1565-1570, 2011.
PubMed
6) Chen, D. S. and Mellman, I.:Oncology meets immunology:The cancer-immunity cycle. Immunity, 39:1-10, 2013.
PubMed
7) Galluzzi, L., Buque, A., Kepp, O., Zitvogel, L. and Kroemer, G.:Immunogenic cell death in cancer and infectious disease. Nat. Rev. Immunol., 17:97-111, 2017.
PubMed
8) Kroemer, G., Galluzzi, L., Kepp, O. and Zitvogel, L.:Immunogenic cell death in cancer therapy. Annu. Rev. Immunol., 31:51-72, 2013.
PubMed
9) Obeid, M., Tesniere, A., Ghiringhelli, F., Fimia, G. M., Apetoh, L., Perfettini, J. L., Castedo, M., Mignot, G., Panaretakis, T., Casares, N., Metivier, D., Larochette, N., van Endert, P., Ciccosanti, F., Piacentini, M., Zitvogel, L. and Kroemer, G.:Calreticulin exposure dictates the immunogenicity of cancer cell death. Nat. Med., 13:54-61, 2007.
PubMed
10) Yadav, M., Jhunjhunwala, S., Phung, Q. T., Lupardus, P., Tanguay, J., Bumbaca, S., Franci, C., Cheung, T. K., Fritsche, J., Weinschenk, T., Modrusan, Z., Mellman, I., Lill, J. R. and Delamarre, L.:Predicting immunogenic tumour mutations by combining mass spectrometry and exome sequencing. Nature, 515:572-576, 2014.
PubMed
11) Tran, E., Ahmadzadeh, M., Lu, Y. C., Gros, A., Turcotte, S., Robbins, P. F., Gartner, J. J., Zheng, Z., Li, Y. F., Ray, S., Wunderlich, J. R., Somerville, R. P. and Rosenberg, S. A.:Immunogenicity of somatic mutations in human gastrointestinal cancers. Science, 350:1387-1390, 2015.
PubMed
12) Kreiter, S., Vormehr, M., van de Roemer, N., Diken, M., Lower, M., Diekmann, J., Boegel, S., Schrors, B., Vascotto, F., Castle, J. C., Tadmor, A. D., Schoenberger, S. P., Huber, C., Tureci, O. and Sahin, U.:Mutant MHC class II epitopes drive therapeutic immune responses to cancer. Nature, 520:692-696, 2015.
PubMed
13) Kantoff, P. W., Higano, C. S., Shore, N. D., Berger, E. R., Small, E. J., Penson, D. F., Redfern, C. H., Ferrari, A. C., Dreicer, R., Sims, R. B., Xu, Y., Frohlich, M. W. and Schellhammer, P. F.;IMPACT Study Investigators:Sipuleucel-T immunotherapy for castration-resistant prostate cancer. N. Engl. J. Med., 363:411-422, 2010.
 
14) Sadelain, M.:CD19 CAR T cells. Cell, 171:1471, 2017.
 
15) Davila, M. L. and Brentjens, R. J.:CD19-targeted CAR T cells as novel cancer immunotherapy for relapsed or refractory B-cell acute lymphoblastic leukemia. Clin. Adv. Hematol. Oncol., 14:802-808, 2016.
PubMed
16) Abramson, J. S., McGree, B., Noyes, S., Plummer, S., Wong, C., Chen, Y. B., Palmer, E., Albertson, T., Ferry, J. A. and Arrillaga-Romany, I. C.:Anti-CD19 CAR T cells in CNS diffuse large-B-cell lymphoma. N. Engl. J. Med., 377:783-784, 2017.
 
17) Maude, S. L., Laetsch, T. W., Buechner, J., Rives, S., Boyer, M., Bittencourt, H., Bader, P., Verneris, M. R., Stefanski, H. E., Myers, G. D., Qayed, M., De Moerloose, B., Hiramatsu, H., Schlis, K., Davis, K. L., Martin, P. L., Nemecek, E. R., Yanik, G. A., Peters, C., Baruchel, A., Boissel, N., Mechinaud, F., Balduzzi, A., Krueger, J., June, C. H., Levine, B. L., Wood, P., Taran, T., Leung, M., Mueller, K. T., Zhang, Y., Sen, K., Lebwohl, D., Pulsipher, M. A. and Grupp, S. A.:Tisagenlecleucel in children and young adults with B-Cell lymphoblastic leukemia. N. Engl. J. Med., 378:439-448, 2018.
 
18) Mullard, A.:FDA approves first BCMA-targeted CAR-T cell therapy. Nat. Rev. Drug Discov., 20:332, 2021.
PubMed
19) Dieu-Nosjean, M. C., Goc, J., Giraldo, N. A., Sautes-Fridman, C. and Fridman, W. H.:Tertiary lymphoid structures in cancer and beyond. Trends Immunol., 35:571-580, 2014.
PubMed
20) Moussion, C. and Girard, J. P.:Dendritic cells control lymphocyte entry to lymph nodes through high endothelial venules. Nature, 479:542-546, 2011.
PubMed
21) Girard, J. P., Moussion, C. and Forster, R.:HEVs, lymphatics and homeostatic immune cell trafficking in lymph nodes. Nat. Rev. Immunol., 12:762-773, 2012.
PubMed
22) Onder, L., Danuser, R., Scandella, E., Firner, S., Chai, Q., Hehlgans, T., Stein, J. V. and Ludewig, B.:Endothelial cell-specific lymphotoxin-β receptor signaling is critical for lymph node and high endothelial venule formation. J. Exp. Med., 210:465-473, 2013.
 
23) Allen, E., Jabouille, A., Rivera, L. B., Lodewijckx, I., Missiaen, R., Steri, V., Feyen, K., Tawney, J., Hanahan, D., Michael, I. P. and Bergers, G.:Combined antiangiogenic and anti-PD-L1 therapy stimulates tumor immunity through HEV formation. Sci. Transl. Med., 9:eaak9679, 2017.
PubMed

[17] 遺伝子改変T細胞

P.109 掲載の参考文献
1) Rosenberg, S. A., Lotze, M. T., Muul, L. M., Chang, A. E., Avis, F. P., Leitman, S., Linehan, W. M., Robertson, C. N., Lee, R. E., Rubin, J. T., Seipp, C. A., Simpson, C. G. and White, D. E.:A progress report on the treatment of 157 patients with advanced cancer using lymphokine-activated killer cells and interleukin-2 or high-dose interleukin-2 alone. N. Engl. J. Med., 316:889-897, 1987.
PubMed
2) Rosenberg, S. A., Packard, B. S., Aebersold, P. M., Solomon, D., Topalian, S. L., Toy, S. T., Simon, P., Lotze, M. T., Yang, J. C. and Seipp, C. A.:Use of tumor-infiltrating lymphocytes and interleukin-2 in the immunotherapy of patients with metastatic melanoma:A preliminary report. N. Engl. J. Med., 319:1676-1680, 1988.
PubMed
3) Rosenberg, S. A.:Cell transfer immunotherapy for metastatic solid cancer:What clinicians need to know. Nat. Rev. Clin. Oncol., 8:577-585, 2011.
PubMed
4) Morgan, R. A., Dudley, M. E., Wunderlich, J. R., Hughes, M. S., Yang, J. C., Sherry, R. M., Royal, R. E., Topalian, S. L., Kammula, U. S., Restifo, N. P., Zheng, Z., Nahvi, A., de Vries, C. R., Rogers-Freezer, L. J., Mavroukakis, S. A. and Rosenberg, S. A.:Cancer regression in patients after transfer of genetically engineered lymphocytes. Science, 314:126-129, 2006.
PubMed
5) Robbins, P. F., Morgan, R. A., Feldman, S. A., Yang, J. C., Sherry, R. M., Dudley, M. E., Wunderlich, J. R., Nahvi, A. V., Helman, L. J., Mackall, C. L., Kammula, U. S., Hughes, M. S., Restifo, N. P., Raffeld, M., Lee, C. C., Levy, C. L., Li, Y. F., El-Gamil, M., Schwarz, S. L., Laurencot, C. and Rosenberg, S. A.:Tumor regression in patients with metastatic synovial cell sarcoma and melanoma using genetically engineered lymphocytes reactive with NY-ESO-1. J. Clin. Oncol., 29:917-924, 2011.
PubMed
6) Robbins, P. F., Kassim, S. H., Tran, T. L. N., Crystal, J. S., Morgan, R. A., Feldman, S. A., Yang, J. C., Dudley, M. E., Wunderlich, J. R., Sherry, R. M., Kammula, U. S., Hughes, M. S., Restifo, N. P., Raffeld, M., Lee, C. C. R., Li, Y. F., El-Gamil, M. and Rosenberg, S. A.:A pilot trial using lymphocytes genetically engineered with an NY-ESO-1-reactive T-cell receptor:Long-term follow-up and correlates with response. Clin. Cancer Res., 21:1019-1027, 2015.
 
7) Gill, S., Tasian, S. K., Ruella, M., Shestova, O., Li, Y., Porter, D. L., Carroll, M., Danet-Desnoyers, G., Scholler, J., Grupp, S. A., June, C. H. and Kalos, M.:Preclinical targeting of human acute myeloid leukemia and myeloablation using chimeric antigen receptor-modified T cells. Blood, 123:2343-2354, 2014.
PubMed
8) Porter, D. L., Levine, B. L., Kalos, M., Bagg, A. and June, C. H.:Chimeric antigen receptor-modified T cells in chronic lymphoid leukemia. N. Engl. J. Med., 365:725-733, 2011.
PubMed
9) Grupp, S. A., Kalos, M., Barrett, D., Aplenc, R., Porter, D. L., Rheingold, S. R., Teachey, D. T., Chew, A., Hauck, B., Wright, J. F., Milone, M. C., Levine, B. L. and June, C. H.:Chimeric antigen receptor-modified T cells for acute lymphoid leukemia. N. Engl. J. Med., 368:1509-1518, 2013.
PubMed
10) Giavridis, T., van der Stegen, S. J. C., Eyquem, J., Hamieh, M., Piersigilli, A. and Sadelain, M.:CAR T cell-induced cytokine release syndrome is mediated by macrophages and abated by IL-1 blockade. Nat. Med., 24:731-738, 2018.
 
11) Norelli, M., Camisa, B., Barbiera, G., Falcone, L., Purevdorj, A., Genua, M., Sanvito, F., Ponzoni, M., Doglioni, C., Cristofori, P., Traversari, C., Bordignon, C., Ciceri, F., Ostuni, R., Bonini, C., Casucci, M. and Bondanza, A.:Monocyte-derived IL-1 and IL-6 are differentially required for cytokine-release syndrome and neurotoxicity due to CAR T cells. Nat. Med., 24:739-748, 2018.
 
12) Lee, D. W., Santomasso, B. D., Locke, F. L., Ghobadi, A., Turtle, C. J., Brudno, J. N., Maus, M. V., Park, J. H., Mead, E., Pavletic, S., Go, W. Y., Eldjerou, L., Gardner, R. A., Frey, N., Curran, K. J., Peggs, K., Pasquini, M., DiPersio, J. F., van den Brink, M. R. M., Komanduri, K. V., Grupp, S. A. and Neelapu, S. S.:ASTCT consensus grading for cytokine release syndrome and neurologic toxicity associated with immune effector cells. Biol. Blood Marrow Transplant., 25:625-638, 2019.
PubMed
13) Morgan, R. A., Chinnasamy, N., Abate-Daga, D., Gros, A., Robbins, P. F., Zheng, Z., Dudley, M. E., Feldman, S. A., Yang, J. C., Sherry, R. M., Phan, G. Q., Hughes, M. S., Kammula, U. S., Miller, A. D., Hessman, C. J., Stewart, A. A., Restifo, N. P., Quezado, M. M., Alimchandani, M., Rosenberg, A. Z., Nath, A., Wang, T., Bielekova, B., Wuest, S. C., Akula, N., Mc-Mahon, F. J., Wilde, S., Mosetter, B., Schendel, D. J., Laurencot, C. M. and Rosenberg, S. A.:Cancer regression and neurological toxicity following anti-MAGE-A3 TCR gene therapy. J. Immunother., 36:133-151, 2013.
PubMed
14) Linette, G. P., Stadtmauer, E. A., Maus, M. V., Rapoport, A. P., Levine, B. L., Emery, L., Litzky, L., Bagg, A., Carreno, B. M., Cimino, P. J., Binder-Scholl, G. K., Smethurst, D. P., Gerry, A. B., Pumphrey, N. J., Bennett, A. D., Brewer, J. E., Dukes, J., Harper, J., Tayton-Martin, H. K., Jakobsen, B. K., Hassan, N. J., Kalos, M. and June, C. H.:Cardiovascular toxicity and titin cross-reactivity of affinity-enhanced T cells in myeloma and melanoma. Blood, 122:863-871, 2013.
PubMed
15) Grada, Z., Hegde, M., Byrd, T., Shaffer, D. R., Ghazi, A., Brawley, V. S., Corder, A., Schonfeld, K., Koch, J., Dotti, G., Heslop, H. E., Gottschalk, S., Wels, W. S., Baker, M. L. and Ahmed, N.:TanCAR:A novel bispecific chimeric antigen receptor for cancer immunotherapy. Mol. Ther. Nucleic. Acids, 2:e105, 2013.
PubMed
16) Schneider, D., Xiong, Y., Wu, D., Nolle, V., Schmitz, S., Haso, W., Kaiser, A., Dropulic, B. and Orentas, R. J.:A tandem CD19/CD20 CAR lentiviral vector drives on-target and off-target antigen modulation in leukemia cell lines. J. Immunother. Cancer, 5:42, 2017.
 
17) Maude, S. L., Frey, N., Shaw, P. A., Aplenc, R., Barrett, D. M., Bunin, N. J., Chew, A., Gonzalez, V. E., Zheng, Z., Lacey, S. F., Mahnke, Y. D., Melenhorst, J. J., Rheingold, S. R., Shen, A., Teachey, D. T., Levine, B. L., June, C. H., Porter, D. L. and Grupp, S. A.:Chimeric antigen receptor T cells for sustained remissions in leukemia. N. Engl. J. Med., 371:1507-1517, 2014.
PubMed
18) Rosenberg, S. A., Yang, J. C., Sherry, R. M., Kammula, U. S., Hughes, M. S., Phan, G. Q., Citrin, D. E., Restifo, N. P., Robbins, P. F., Wunderlich, J. R., Morton, K. E., Laurencot, C. M., Steinberg, S. M., White, D. E. and Dudley, M. E.:Durable complete responses in heavily pretreated patients with metastatic melanoma using T-cell transfer immunotherapy. Clin. Cancer Res., 17:4550-4557, 2011.
PubMed
19) D'Angelo, S. P., Melchiori, L., Merchant, M. S., Bernstein, D., Glod, J., Kaplan, R., Grupp, S., Tap, W. D., Chagin, K., Binder, G. K., Basu, S., Lowther, D. E., Wang, R., Bath, N., Tipping, A., Betts, G., Ramachandran, I., Navenot, J. M., Zhang, H., Wells, D. K., Van Winkle, E., Kari, G., Trivedi, T., Holdich, T., Pandite, L., Amado, R. and Mackall, C. L.:Antitumor activity associated with prolonged persistence of adoptively transferred NY-ESO-1 c259T cells in synovial sarcoma. Cancer Discov., 8:944-957, 2018.
PubMed
20) Odorizzi, P. M., Pauken, K. E., Paley, M. A., Sharpe, A. and Wherry, E. J.:Genetic absence of PD-1 promotes accumulation of terminally differentiated exhausted CD8+ T cells. J. Exp. Med., 212:1125-1137, 2015.
PubMed
21) Scott, A. C., Dundar, F., Zumbo, P., Chandran, S. S., Klebanoff, C. A., Shakiba, M., Trivedi, P., Menocal, L., Appleby, H., Camara, S., Zamarin, D., Walther, T., Snyder, A., Femia, M. R., Comen, E. A., Wen, H. Y., Hellmann, M. D., Anandasabapathy, N., Liu, Y., Altorki, N. K., Lauer, P., Levy, O., Glickman, M. S., Kaye, J., Betel, D., Philip, M. and Schietinger, A.:TOX is a critical regulator of tumour-specific T cell differentiation. Nature, 571:270-274, 2019.
PubMed
22) Kishton, R. J., Sukumar, M. and Restifo, N. P.:Metabolic regulation of T cell longevity and function in tumor immunotherapy. Cell Metab., 26:94-109, 2017.
PubMed
23) Roth, T. L., Li, P. J., Blaeschke, F., Nies, J. F., Apathy, R., Mowery, C., Yu, R., Nguyen, M. L. T., Lee, Y., Truong, A., Hiatt, J., Wu, D., Nguyen, D. N., Goodman, D., Bluestone, J. A., Ye, C. J., Roybal, K., Shifrut, E. and Marson, A.:Pooled knockin targeting for genome engineering of cellular immunotherapies. Cell, 181:728-744, 2020.
PubMed
24) Adachi, K., Kano, Y., Nagai, T., Okuyama, N., Sakoda, Y. and Tamada, K.:IL-7 and CCL19 expression in CAR-T cells improves immune cell infiltration and CAR-T cell survival in the tumor. Nat. Biotechnol., 36:346-351, 2018.
 
25) Caruana, I., Savoldo, B., Hoyos, V., Weber, G., Liu, H., Kim, E. S., Ittmann, M. M., Marchetti, D. and Dotti, G.:Heparanase promotes tumor infiltration and antitumor activity of CAR-redirected T lymphocytes. Nat. Med., 21:524-529, 2015.
PubMed
26) Qasim, W., Zhan, H., Samarasinghe, S., Adams, S., Amrolia, P., Stafford, S., Butler, K., Rivat, C., Wright, G., Somana, K., Ghorashian, S., Pinner, D., Ahsan, G., Gilmour, K., Lucchini, G., Inglott, S., Mifsud, W., Chiesa, R., Peggs, K. S., Chan, L., Farzaneh, F., Thrasher, A. J., Vora, A., Pule, M. and Veys, P.:Molecular remission of infant B-ALL after infusion of universal TALEN gene-edited CAR T cells. Sci. Transl. Med., 9:eaaj2013, 2017.
 
27) Poirot, L., Philip, B., Schiffer-Mannioui, C., Le Clerre, D., Chion-Sotinel, I., Derniame, S., Potrel, P., Bas, C., Lemaire, L., Galetto, R., Lebuhotel, C., Eyquem, J., Cheung, G. W. K., Duclert, A., Gouble, A., Arnould, S., Peggs, K., Pule, M., Scharenberg, A. M. and Smith, J.:Multiplex genome-edited T-cell manufacturing platform for "off-the-shelf" adoptive T-cell immunotherapies. Cancer Res., 75:3853-3864, 2015.
PubMed
28) Ren, J., Liu, X., Fang, C., Jiang, S., June, C. H. and Zhao, Y.:Multiplex genome editing to generate universal CAR T cells resistant to PD1 inhibition. Clin. Cancer Res., 23:2255-2266, 2017.
 
29) Benjamin, R., Graham, C., Yallop, D., Jozwik, A., Mirci-Danicar, O. C., Lucchini, G., Pinner, D., Jain, N., Kantarjian, H., Boissel, N., Maus, M. V., Frigault, M. J., Baruchel, A., Mohty, M., Gianella-Borradori, A., Binlich, F., Balandraud, S., Vitry, F., Thomas, E., Philippe, A., Fouliard, S., Dupouy, S., Marchiq, I., Almena-Carrasco, M., Ferry, N., Arnould, S., Konto, C., Veys, P. and Qasim, W.;UCART19 Group:Genome-edited, donor-derived allogeneic anti-CD19 chimeric antigen receptor T cells in paediatric and adult B-cell acute lymphoblastic leukaemia:Results of two phase 1 studies. Lancet, 396:1885-1894, 2020.
PubMed
30) Di Stasi, A., Tey, S. K., Dotti, G., Fujita, Y., Kennedy-Nasser, A., Martinez, C., Straathof, K., Liu, E., Durett, A. G., Grilley, B., Liu, H., Cruz, C. R., Savoldo, B., Gee, A. P., Schindler, J., Krance, R. A., Heslop, H. E., Spencer, D. M., Rooney, C. M. and Brenner, M. K.:Inducible apoptosis as a safety switch for adoptive cell therapy. N. Engl. J. Med., 365:1673-1683, 2011.
PubMed
31) Maeda, T., Nagano, S., Kashima, S., Terada, K., Agata, Y., Ichise, H., Ohtaka, M., Nakanishi, M., Fujiki, F., Sugiyama, H., Kitawaki, T., Kadowaki, N., Takaori-Kondo, A., Masuda, K. and Kawamoto, H.:Regeneration of tumor-antigen-specific cytotoxic T lymphocytes from iPSCs transduced with exogenous TCR genes. Mol. Ther. Methods Clin. Dev., 19:250-260, 2020.
 

[18] がん免疫療法の未来に向けて ; Beyond The Guideline

P.116 掲載の参考文献
1) Coley, W. B.:The treatment of malignant tumors by repeated inoculations of erysipelas:With a report of ten original cases. Am. J. Med. Sci., 105:487-511, 1893.
 
2) Banchereau, J. and Steinman, R. M.:Dendritic cells and the control of immunity. Nature, 392:245-252, 1998.
PubMed
3) Boon, T., Cerottini, J. C., Van den Eynde, B., van der Bruggen, P. and Van Pel, A.:Tumor antigens recognized by T lymphocytes. Annu. Rev. Immunol., 12:337-365, 1994.
 
4) Grosso, J. F., Kelleher, C. C., Harris, T. J., Maris, C. H., Hipkiss, E. L., De Marzo, A., Anders, R., Netto, G., Getnet, D., Bruno, T. C., Goldberg, M. V., Pardoll, D. M. and Drake, C. G.:LAG-3 regulates CD8+ T cell accumulation and effector function in murine self-and tumor-tolerance systems. J. Clin. Invest., 117:3383-3392, 2007.
PubMed
5) Tawbi, H. A., Schadendorf, D., Lipson, E. J., Ascierto, P. A., Matamala, L., Castillo Gutierrez, E., Rutkowski, P., Gogas, H. J., Lao, C. D., De Menezes, J. J., Dalle, S., Arance, A., Grob, J. J., Srivastava, S., Abaskharoun, M., Hamilton, M., Keidel, S., Simonsen, K. L., Sobiesk, A. M., Li, B., Hodi, F. S. and Long, G. V.;RELATIVITY-047 Investigators:Relatlimab and nivolumab versus nivolumab in untreated advanced melanoma. N. Engl. J. Med., 386:24-34, 2022.
PubMed
6) Koguchi, K., Anderson, D. E., Yang, L., O'Connor, K. C., Kuchroo, V. K. and Hafler, D. A.:Dysregulated T cell expression of TIM3 in multiple sclerosis. J. Exp. Med., 203:1413-1418, 2006.
 
7) Qin, S., Dong, B., Yi, M., Chu, Q. and Wu, K.:Prognostic values of TIM-3 expression in patients with solid tumors:A meta-analysis and database evaluation. Front. Oncol., 10:1288, 2020.
 
8) Mach, N., Curigliano, G., Santoro, A., Kim, D-W., Tai, D. W. M., Hodi, S., Wilgenhof, S., Doi, T., Longmire, T., Sun, H., Xyrafas, A., Gutzwiller, S., Manenti, L. and Lin, C.:Phase (Ph) II study of MBG453+ spartalizumab in patients (pts) with non-small cell lung cancer (NSCLC) and melanoma pretreated with anti-PD-1/L1 therapy. Ann. Oncol., 30:v491-v492, 2019.
 
9) Marin-Acevedo, J. A., Kimbrough, E. O. and Lou, Y.:Next generation of immune checkpoint inhibitors and beyond. J. Hematol. Oncol., 14:45, 2021.
PubMed
10) Qin, S., Xu, L., Yi, M., Yu, S., Wu, K. and Luo, S.:Novel immune checkpoint targets:Moving beyond PD-1 and CTLA-4. Mol. Cancer, 18:155, 2019.
 
11) Chocarro, L., Arasanz, H., Fernandez-Rubio, L., Blanco, E., Echaide, M., Bocanegra, A., Teijeira, L., Garnica, M., Morilla, I., Martinez-Aguillo, M., Pineiro-Hermida, S., Ramos, P., Lasarte, J. J., Vera, R., Kochan, G. and Escors, D.:CAR-T cells for the treatment of lung cancer. Life, 12:561, 2022.
PubMed
12) Zhong, S., Cui, Y., Liu, Q. and Chen, S.:CAR-T cell therapy for lung cancer:A promising but challenging future. J. Thorac. Dis., 12:4516-4521, 2020.
 
13) Yao, Y., Hu, Y. and Wang, F.:Trispecific antibodies for cancer immunotherapy. Immunology, 169:389-399, 2023.
 
14) Antonia, S. J., Villegas, A., Daniel, D., Vicente, D., Murakami, S., Hui, R., Yokoi, T., Chiappori, A., Lee, K. H., de Wit, M., Cho, B. C., Bourhaba, M., Quantin, X., Tokito, T., Mekhail, T., Planchard, D., Kim, Y. C., Karapetis, C. S., Hiret, S., Ostoros, G., Kubota, K., Gray, J. E., Paz-Ares, L., de Castro Carpeno, J., Wadsworth, C., Melillo, G., Jiang, H., Huang, Y., Dennis, P. A. and Ozguroglu, M.;PACIFIC Investigators:Durvalumab after chemoradiotherapy in stage III non-small-cell lung cancer. N. Engl. J. Med., 377:1919-1929, 2017.
PubMed
15) Spigel, D. R., Faivre-Finn, C., Gray, J. E., Vicente, D., Planchard, D., Paz-Ares, L., Vansteenkiste, J. F., Garassino, M. C., Hui, R., Quantin, X., Rimner, A., Wu, Y. L., Ozguroglu, M., Lee, K. H., Kato, T., de Wit, M., Kurata, T., Reck, M., Cho, B. C., Senan, S., Naidoo, J., Mann, H., Newton, M., Thiyagarajah, P. and Antonia, S. J.:Five-year survival outcomes from the PACIFIC trial:Durvalumab after chemoradiotherapy in stage III non-small-cell lung cancer. J. Clin. Oncol., 40:1301-1311, 2022.
PubMed
16) Felip, E., Altorki, N., Zhou, C., Csoszi, T., Vynnychenko, I., Goloborodko, O., Luft, A., Akopov, A., Martinez-Marti, A., Kenmotsu, H., Chen, Y. M., Chella, A., Sugawara, S., Voong, D., Wu, F., Yi, J., Deng, Y., McCleland, M., Bennett, E., Gitlitz, B. and Wakelee, H.;IMpower010 Investigators:Adjuvant atezolizumab after adjuvant chemotherapy in resected stage IB-IIIA non-small-cell lung cancer (IMpower010):A randomised, multicentre, open-label, phase 3 trial. Lancet, 398:1344-1357, 2021.
PubMed
17) Woodard, G. A., Li, A. and Boffa, D. J.:Role of adjuvant therapy in T1-2N0 resected non-small cell lung cancer. J. Thorac. Cardiovasc. Surg., 163:1685-1692, 2022.
PubMed
18) Chen, D. S. and Mellman, I.:Oncology meets immunology:The cancer-immunity cycle. Immunity, 39:1-10, 2013.
PubMed
19) Fukuhara, M., Muto, S., Inomata, S., Yamaguchi, H., Mine, H., Takagi, H., Ozaki, Y., Watanabe, M., Inoue, T., Yamaura, T., Okabe, N., Matsumura, Y., Hasegawa, T., Osugi, J., Hoshino, M., Higuchi, M., Shio, Y. and Suzuki, H.:The clinical significance of tertiary lymphoid structure and its relationship with peripheral blood characteristics in patients with surgically resected non-small cell lung cancer:A single-center, retrospective study. Cancer Immunol. Immunother., 71:1129-1137, 2022.
PubMed
20) Fridman, W. H., Petitprez, F., Meylan, M., Chen, T. W., Sun, C. M., Roumenina, L. T. and Sautes-Fridman, C.:B cells and cancer:To B or not to B? J. Exp. Med., 218:e20200851, 2021.
 
21) Meylan, M., Petitprez, F., Becht, E., Bougouin, A., Pupier, G., Calvez, A., Giglioli, I., Verkarre, V., Lacroix, G., Verneau, J., Sun, C. M., Laurent-Puig, P., Vano, Y. A., Elaidi, R., Mejean, A., Sanchez-Salas, R., Barret, E., Cathelineau, X., Oudard, S., Reynaud, C. A., de Reynies, A., Sautes-Fridman, C. and Fridman, W. H.:Tertiary lymphoid structures generate and propagate anti-tumor antibody-producing plasma cells in renal cell cancer. Immunity, 55:527-541, 2022.
PubMed
22) Anderson, N. R., Minutolo, N. G., Gill, S. and Klichinsky, M.:Macrophage-based approaches for cancer immunotherapy. Cancer Res., 81:1201-1208, 2021.
PubMed

書評

最近チェックした商品履歴

Loading...